Preface
Advancing Human Participant Research
Public Comment Summary

The University of Minnesota has a long history of exceptional clinical research that has contributed tremendously to the better health and well being of our society. Thus, the institution’s commitment to clinical research is unassailable, and we believe strongly in the need to continue excellence in this area.

The implementation team recommends significant and innovative changes to our human research protection program. The intent of these changes is to cultivate a culture that ensures the primacy of the UMN and all of its investigator’s duty to keep the well being of patients who become research participants at the center of policies and procedures, while ensuring our commitment to clinical research and our faculty.

Based on these principles and desire for the broadest adoption possible, the team presented a draft work plan to the public for their review and comment on May 18, 2015 through June 1, 2015. The team received over 70 individual and multi-individual (grouped) comments to the draft plan. Many centered on concerns about undue burden and proposed policy changes regarding conflict of interest; suggestions for community engagement; concerns about changes to scientific review; and questions about the applicability of the changes to the Social and Behavioral IRBs. The final work plan submitted to the President and the Board of Regents incorporates those comments. The specific comments received and team response to these comments are published on the team’s website: http://research.umn.edu/advancehsr/index.html

Given the time frame available to the team to produce a report in response to the charge from the President, and the scope of the charge, it was not possible to fully work out all the operational aspects of every recommendation. Having said that, the team wants to assure all stakeholders that as the recommendations are adopted, significant input from the clinical research community will continue to be sought to make sure that they are done thoughtfully and appropriately.

The team wishes to thank all those who submitted very thoughtful comments on the draft implementation team’s report. Many of the comments led to substantive changes in the report. These comments also underscore the reality that while this work plan represents the roadmap to reenergize the culture of human studies research at the UMN, implementation of these recommendations will require many additional collegial discussions and engagement by the entire University community.
Implementing the Recommendations of the External Review of the University of Minnesota Human Research Protection Program

Work Plan

June 11, 2015

Implementation Team Members:

Joanne Billings, M.D., MPH, Assistant Professor, Department of Medicine
William Durfee, Ph.D., Morse Alumni Distinguished Teaching Professor, Mechanical Engineering
Debra Dykhuis, Executive Director, Human Research Protection Program
Paul F Goering, M.D., Vice President, Allina Mental Health
Brian Herman, Ph.D., Vice President for Research, Co-Vice Chair
Brooks Jackson, M.D., M.B.A, Dean, Medical School; Vice President for Health Sciences, Co-Vice Chair
Gail Klatt, Associate Vice President, Office of Internal Audit, Ex Officio
Steven Miles, M.D., Professor and Maas Family Endowed Chair in Bioethics, Center for Bioethics; Professor, Department of Medicine
Timothy Schacker, M.D., Professor, Department of Medicine
Naomi Scheman, Ph.D., Professor, Department of Philosophy
William J. Tremaine, M.D., Professor of Medicine, Mayo Clinic, Chair
Daniel Weisdorf, M.D., Professor, Department of Medicine
Carolyn S Wilson, RN, Executive Vice President and Chief Operating Officer of Fairview; Co-President, University of Minnesota Health
Jean Wyman, Ph.D, RN, GNP-BC, FAAN, FGSA Professor and Cora Meidl Siehl Endowed Chair in Nursing Research
# Table of Contents

1. Executive Summary ...................................................................................................................... 2

2. Introduction ..................................................................................................................................... 10
   2.1. Reason for the Implementation team ........................................................................................ 10
   2.2. Team Charge ............................................................................................................................... 12
   2.3. Team Process .............................................................................................................................. 12
   2.4. Structure of the Report ............................................................................................................... 13

3. Intent of the Report and Cultivating a Culture of Ethics .............................................................. 13

4. IRB Membership ............................................................................................................................ 17

5. IRB Protocol Review Process ....................................................................................................... 21

6. Scientific Review of Studies ......................................................................................................... 22

7. Fairview University Research Oversight Committee .................................................................... 26

8. Monitoring of Studies .................................................................................................................... 27

9. For Cause Investigations ............................................................................................................... 29

10. Human Research Participants Who Have Impaired or Fluctuating Capacity to Consent .......... 30

11. Department of Psychiatry .......................................................................................................... 42

12. Engaging Research Participants ................................................................................................. 46

13. Education and Training of Investigators ..................................................................................... 49

14. Accountability Metrics ................................................................................................................ 51

15. Managing Conflicts of Interest .................................................................................................. 54

16. Community Oversight Board ..................................................................................................... 56

17. External Advisor .......................................................................................................................... 59

18. Post-Report Activities .................................................................................................................. 61

19. Analysis of Resources Required for Implementation .................................................................... 62

20. Conclusion .................................................................................................................................... 64

21. Appendices .................................................................................................................................. 65
   21.1. Advancing Human Subjects Research Organizational Chart ................................................ 65
   21.3. List of External Review Recommendations ............................................................................. 67
1. Executive Summary

Introduction

The University of Minnesota rightfully takes pride in the longstanding tradition of excellence in research by the U of M faculty and staff who work diligently to improve the lives of Minnesotans and others around the world.

Following the receipt of two independent assessments (the External Review report and the Office of the Legislative Auditor report) of the University of Minnesota’s Human Research Protection Program (that focused on consenting of individuals with diminished mental capacity and the issues surrounding the death of Dan Markingson), President Eric Kaler jointly charged the Vice President for Research and Vice President for Health Sciences with creating an Implementation team. The goal of the team was to review and implement the recommendations of the External Review as well as consider other changes to enhance the current University Human Research Protection Program (HRPP) such that it could serve as a national model for other institutions to emulate.

The Implementation team met weekly to discuss and refine action plans related to recommendations and groups of recommendations, which resulted in the action plan detailed in the body of this report. The plan was put forth by the implementation team for public comment and review by those inside and outside the U of M.

Key Parts of the Work Plan

Below are the key components of the work plan. For the complete details associated with each of these components, see the body of the report.

- *Cultivating a culture of ethics:* The team recognizes the responsibility of the U of M and each individual research investigator to keep the rights and welfare of research participants at the center of all research activities. The U of M must maintain the
highest ethical standards for the conduct of research with research participants. That culture will come from fostering University-wide conversations, better educating research investigators, and setting standards that commit the U of M to an ethical culture of accountability that is a national model for others to emulate.

Recommendations for how to achieve this national model are included throughout this report. Important and central to these goals, we strongly recommend creating a Fairview/University joint senior leadership team with representatives from the Fairview Research Office, Fairview clinical staff, University Academic Health Center, UM Physicians and the University Office of the Vice President for Research (herein after referred to as FUROC, see section 7) to evaluate the success of the changes made as a result of this report and constantly look for opportunities to enhance the culture changes that need to happen. This team will report its findings to U of M and Fairview leadership.

- **Institutional Review Board (IRB) membership:** The team includes in this report a process to reorganize the IRB so that it can effectively provide thorough, efficient, and timely assessments of all aspects of the proposed research. This reorganization includes a significant increase in the number of review panels for evaluation of biomedical research and increasing the number of people who serve on those panels, as well as to set out guidelines to limit the workload and review process so that time can be given for a more careful consideration of each application. Further, we recommend that IRB members be compensated. The team also states that serving on the IRB must be viewed as a valued service activity for promotion and tenure.

- **IRB review process:** IRB meetings must be conducted in a uniform format that includes meaningful and documented discussions that focus on regulatory requirements for approval and ethical norms for human research participant studies. An increase in the IRB administrative staff will be required so that a thorough pre-review process can occur that ensures the full IRB committee is focused on studies involving greater than minimal
risk or those required by federal regulations to be reviewed at a convened meeting. Significant investments in an online IRB review management system will need to be made. The team also recommends that benchmark visits to IRBs at other institutions be made to better inform IRB members.

- **Scientific review:** Conducting a proper scientific review by qualified individuals who have no conflict of interest is paramount and has proven to be difficult when the review is handled by the department hosting the research. We recommend eliminating departmental peer review and creating a process in the HRPP to manage scientific reviews. That process will include defining the qualifications of and conflicts for peer reviewers.

- **Monitoring of studies:** The system to monitor investigators compliance with IRB approved activities needs to be strengthened. We recommend resources be made available to increase the number of PAR’s that are completed each year, particularly for research conducted at Fairview. Results of each investigation need to be reported to the FUROC (see section 7) as well as department, center, and college leadership to ensure that everyone who is responsible for the conduct of that research is aware when problems are found.

- **For-cause investigations:** Investigation into allegations of investigator misconduct or ethical violations should also be relocated from the HRPP to a new OVPR Research Compliance Office function. The research misconduct investigation process already resides in the OVPR. Any findings that result from an investigation should be reported to the FUROC (see section 7) as well as department, center, and college leadership. In addition, communication of results should be made to the investigator, complainant (if known), and to the research participant, if applicable.
• *Research participants who have impaired or fluctuating capacity to consent:* The team recognizes that conducting research with participants with impaired capacity is central to the problems identified by the External Review. Included in this report is a detailed discussion of how to define impaired capacity and guidelines for how to identify studies that include a vulnerable population or research participants with impaired capacity. We believe that discussions of capacity should be included at every step of the research design and implementation process. In this report we identify new tools that will be used to assess capacity to consent. We suggest how to qualify investigators and research staff to be responsible for obtaining consent. We mandate the creation and use of a consent capacity monitoring plan that lasts the duration of the study where it is anticipated that capacity to consent may fluctuate, for example, in patients with severe mental or critical illness. We recommend a process of intermittent live consent monitoring by someone appropriately trained and not associated with the research study in those situations where the research participant population is identified as impaired. We identify situations where research participants may be potentially vulnerable to coercion or exploitation and provide a process to ensure coercion or exploitation does not take place. Finally, we state that the definition of who can be a Legally Authorized Representative (LAR) must be standardized and conform to national norms and the laws of the State of Minnesota, and also that a consent advocate should be a regular part of the consent process for vulnerable research participants.

• *Department of Psychiatry:* The Department of Psychiatry routinely engages in research with research participants with impaired consent capacity. However, these studies are not unique to the Department of Psychiatry. We are recommending that appropriate training programs for clinical staff, investigators and IRB members be developed and mandated when research involves a vulnerable population. We also recommend that one of the new IRB panels be dedicated to reviewing studies involving research participants with impaired or fluctuating capacity to consent and that this panel be responsible for all applications that involve this population. To that end we propose the
University of Minnesota Clinical and Translational Research Institute (CTSI) assume management for the conduct of interventional drug and device trials in the Department of Psychiatry. We further recommend that an independent consultant be hired to assess the clinical and research climate concerning psychiatric studies conducted at Fairview to develop a plan that addresses shared concerns and creates a climate where clinical research with psychiatric research participants can occur that meets the highest ethical standards of research possible. We state that an education plan be developed for the two faculty specifically named in the External Review report. Finally it is important to articulate and act on how to improve the process of how research is done, especially in this very important population.

We document in this plan a process in which clinical staff who provide care for psychiatric patients but who are not part of the research team will be able to participate in the early stages of study and protocol development to provide insight on how the study might impact clinical care of the patient and to create an atmosphere of shared responsibility for all aspects of the research study. In addition we recommend a process where engaged community members can have a real voice in how psychiatric research is conducted. We suggest that the FUROC, mentioned above, continuously monitor the research climate and be regularly engaged with groups involved in the clinical research process (CTSI, HRPP, and OVPR) to make suggestions and course corrections.

- **Engaging research participants**: Research participants should be considered part of the research team and their feedback should be an integral part of the process for conducting human research. In addition, a process should exist to deliver information back to the participant on the outcome of the research he or she participated in. Current mechanisms for these activities are insufficient and require considerable strengthening. To that end, we recommend a new staff position in the CTSI Community Engagement Core, a Community Liaison Officer, should be created to provide day-to-day management of the research subject engagement activities and to regularly report
defined metrics to OVPR. We recommend that the CTSI Community Liaison Officer be actively involved in these activities and act as a resource. We recommend a process be adopted to promptly address all reported concerns and that metrics be collected on research participant satisfaction. Finally, we recommend a process to ensure that a plan is in place to share final result with all research participants.

- **Education and training of investigators:** The team strongly believes that appropriate training of investigators is at the core of creating and embracing a culture where research can be conducted that meets the highest ethical standards. We recommend a new position of a Human Research Procedures, Policies and Ethics Education Coordinator within the CTSI or HRPP with coordinated links to the Center for Bioethics. This individual will be responsible for establishing guidelines for minimal expectations for both basic and advanced research compliance and research participant protection training that is reviewed and approved by an oversight process in the HRPP. This individual will ensure that required and optional training modules on appropriate topics are available and kept current. Specific attention should be given to curriculum for advanced training in the use of research participants with limited or fluctuating capacity to consent. Training programs should be developed collaboratively by the HRPP, CTSI, the Center for Bioethics and other U of M resources to address these needs. This process should engage community members, including research participants.

- **Accountability metrics:** As part of implementing the recommendations included in this report, metrics will be collected to assure that the changes made are meeting the expectations of research participants, the University community, and our partners. These metrics also allow for continued quality improvement with the expectation that they will be reviewed at minimum twice each year by the Community Advisory Board and by the new OVPR Research Compliance office.
• **Managing conflicts of interest:** The team recommends that the U of M adopt a more stringent reporting structure than dictated by current policy or Public Health Service (PHS) guidelines. The Implementation team proposes that henceforth, a financial interest, including equity, consulting income, speaker fees, and/or royalties must be disclosed from the first dollar or from contractual rights to receive funds. In addition, the team recommends that in general an investigator may not receive any personal compensation from a company during the time that investigator participates in any new research study funded by that industry sponsor.

• **Community Oversight Board:** The team fully embraces the evolving concept that active participation of the community is integral to the conduct of research involving research participants. We recommend creation of a 12-member board of external academic, professional and community experts. This board will advise the OVPR and the HRPP on best practices for research participant protection. The board will report regularly to OVPR.

• **External advisor:** An international expert with knowledge in research participant protection will be retained and will work with those responsible for implementing the action plan described in this report. The expert will provide input and feedback to the Vice President for Research and Vice President for Health Sciences on progress. The expert will be engaged on a monthly basis until implementation is complete.

• **Required resources:** The current annual budget of the U of M HRPP is $2.2M. The estimated cost for this action plan is a $5.5M one-time cost and an increase to a more extensive HRPP annual budget of $4.4M.
This report, describing how to implement the recommendations, was presented by the Implementation team for a 15-day public comment and review period for those inside and outside the U of M.
2. Introduction

2.1. Reason for the Implementation team

In May 2004, Dan Markingson, while enrolled in a clinical trial of an antipsychotic drug study at the University of Minnesota, committed suicide. Since that time individuals and groups within and outside the U of M have raised questions about the study, how Markingson was recruited to participate as a research participant, his treatment during the study, the circumstances of his suicide, and the adequacy of the subsequent investigations. Following a series of discussions that occurred in Fall 2013, on December 5, 2013 the University of Minnesota Faculty Senate passed a resolution calling for an inquiry to examine current policies, practices, and oversight of clinical research with research participants at the U of M, in particular clinical research involving adult participants with diminished functional abilities, and asked that there be an independent panel to conduct the review. The reasoning behind the resolution was while investigations had been conducted on the Markingson case, those investigations did not address the broader question of whether the U of M’s current policies, procedures and practices reflected best practices in clinical research with research participants and the faculty’s high ambitions for ethical behavior.

In January 2014, Eric Kaler, President of the U of M, endorsed the Senate resolution and charged Brian Herman, Vice President for Research, to oversee the inquiry. In June 2014, the Association for the Accreditation of Human Research Protection Programs (AAHRPP) was awarded a contract to assemble a review team and logistically manage the review process. A panel of six outside experts, selected by AAHRP, was contracted to conduct the review.

The panel conducted its work from August 2014 to March 2015, this included reviewing hundreds of documents, conducting a 2-day site visit where they interviewed 53 people and receiving dozens of comments from stakeholders inside and outside the U of M.
On February 23, 2015, the panel issued a report containing 63 recommendations for
improving the human research protection program at the U of M. The language of the
February report was strong in its statement that while our current program is in many
respects adequate, the U of M must make changes if it wishes to have a leading
program in research participant protection. The External Review’s report is available
at http://research.umn.edu/advancehsr/keydocs.html.

In a separate but related activity, on March 19, 2015 the Office of the Legislative Auditor
released its report that focused on the events surrounding the 2004 death of Dan
Markingson. The Auditor’s report determined that it was not possible to know whether
Dan Markingson’s suicide was connected to his participation in the U of M clinical
research trial, but did state that the Markingson case raised ethical and conflict of
interest issues. Further, the Auditor’s report stated that the U of M was insular and
defensive in its response to the Markingson case. The Auditor recommended that the U
of M fully implement the recommendations in the External Review report. The Auditor’s
report is also available at http://research.umn.edu/advancehsr/keydocs.html.

On March 12, 2015, President Kaler charged Brian Herman, Vice President for Research,
and Brooks Jackson, Vice President for Health Sciences, with the responsibility of
overseeing the implementation of the recommendations of the External Review by
establishing an Implementation team made up of individuals internal and external to
the U of M who had the qualifications and expertise to review the recommendations
and develop a plan to implement them. In addition, at its March 27, 2015 meeting, the
University of Minnesota Board of Regents approved immediate and longer term action
plans to implement the recommendations.
The Implementation team has 13 members, some external to the U of M, and is chaired by Dr. William Tremaine, Professor of Medicine, Mayo Clinic and Director, Mayo Clinic IRB.

During the time of the Implementation team’s work, two additional reports were made available to all team members: (1) a draft State of Minnesota Office of the Legislative Auditor’s report of May 5, 2015 which presented findings from all industry-sponsored studies at the U of M from 2004-2014; and (2) Final IRB Investigation Report Into Fairview Concerns Regarding Psychiatry Research Studies at the University of Minnesota, referred to as the “Oakes report”. This team considered the information from these reports in the recommendations contained in this report. Report 2 above is publically available on the Advancing Human Subjects Research website.

2.2. Team Charge

The Implementation team was specifically charged with the following:

- A work plan to implement the recommendations, to be produced within 60 days
- Accountability metrics for the work plan
- A recommendation regarding necessary resources to implement the recommendation
- Engagement of appropriate critical stakeholders in assisting with the implementation
- Engagement of an external advisor with deep knowledge in human research protection programs, regulations, and law to work with the U of M on the implementation
- A review of best practices regarding conflict of interest for researchers engaged in human research participant studies, including a recommendation on organization or structural changes
- Formation of an oversight committee made up of community leaders and other parties affected by the implementation and the U of M research program

2.3. Team Process

The Implementation team met weekly from April 1, 2015 through May 6, 2015. During those meetings team members presented action plans on each of the 63 recommendations made by the External Review. Each proposed action plan was co-
authored by two or more Implementation team members and was brought to the full team for discussion and debate. Significant between-meeting email and telephone communications were held among team members to review the recommendations and prepare the final work plan.

In addition, the implementation team created a public website, http://research.umn.edu/advancehsr/ that tracked all the activities of the implementation team, provided weekly summaries of the Implementation team meetings, listed relevant documents related to the activities of the Implementation team, and provided information about public hearings and other consultative efforts on this subject held at the U of M. The team also created an email address advancehsr@umn.edu to receive feedback from interested stakeholders at any time.

2.4. Structure of the Report
Sections 3 through 18 of this plan contain the detailed implementation work plan, which is tied to the specific recommendations of the External Review panel. Each recommendation from the External Review report has been given a number and the complete list of recommendations can be found in the Appendix to this report. We have grouped some of the recommendations under broader headings than those used by the External Review panel when we saw overlap or similarities between recommendations.

3. Intent of the Report and Cultivating a Culture of Ethics
Covers External Review report recommendations: 3.1.1, 3.1.2, 3.1.3, 3.1.4, 3.1.5, and 3.6.1, 3.6.2, 3.6.3

The purpose of the University of Minnesota Human Subject Protection Program is to protect the rights and welfare of all research participants who participate in research, especially those with impaired capacity to consent. U of M scientists, clinicians and programs are fundamentally
obliged to promote the welfare of each research participant. We do this with a beneficent regard for their health and a commitment to avoiding harming them. As an academic research center, the U of M seeks to discover and test emerging ideas and products to improve the health of all persons and the health of the broader community. To this latter end, researchers enroll research participants in experimental studies. Notwithstanding the importance of those studies individually or collectively, regard for the individual well-being of those who volunteer to be research participants and respect for their freedom to consent to and to refuse treatment or research interventions must never be eclipsed by the research interests of the U of M or its individual researchers.

The aim of improving the care of research participants who participate in research is simple to state but has many complex parts and ramifications.

First, it entails unambiguously affirming the primacy of the U of M’s and each individual investigator’s duty to keep the well-being of patients who become research participants firmly in mind and at the center of the policies and procedures of the U of M. We must be mindful that individuals who make the gift of consenting to participate as research participants are entrusting us to faithfully promote their well-being and to respect their freely given, informed consent as they enroll in research, and that they retain the right to decline to continue to consent to that research project for any reason but especially as new data, side effects, or unexpected circumstances occur during the course of the study. We are aware of the special responsibilities toward those persons whose capacity to consent to research is impaired during participation in a study or fluctuates during the course of a study.

Second, the research enterprise must recognize that the population of potential research participants is a valuable resource to the community and to the scientific enterprise. The U of M as a whole is a steward of that resource. Any action that harms the trust between potential research participants and researchers affects the entire scientific enterprise. In this sense, one
failure adversely affects the particular study, all present studies, all future studies, and even the broader community.

Third, the work plan of this implementation team must speak to all elements of the health research enterprise and must:

- Provide education in ethics to all of those who oversee and conduct research on human beings.
- Protect and promote the rights and interests of research participants who are vulnerable to various kinds of coerced consent or who lack (or may come to lack) the capacity to consent to (or continue to consent to or decline) continued participation in research.
- Comply with the letter and be committed to the spirit of the laws and regulations that pertain to the treatment of patients and of persons who are enrolled in research.
- Be transparent and accountable in all research activities. This includes a culture where anyone who observes a breach of the ethics or rules for research may report his or her observations without fear of retaliation and with confidence that his or her concerns will be investigated.
- Manage individual and institutional conflicts of interest that potentially undermine the well-being of research participants regardless of whether they arise from financial, career, or personal interests.
- Sustain a culture of engagement among all colleges in the U of M that recognizes the special status of university-based research. This status is grounded in the integrity of academic research, as well as in respect for cultural diversity and for the social, economic, and cultural implications of biomedical research.
- Effectively engage in a dialogue with the broader community that has a stake in benefitting from research and an interest in protecting their loved ones who may participate as research participants.
Reinforce that communication without action is discouraged. In other words, changing the culture on research participant protection is not a communications-driven activity.

The work plan presented here signifies an awareness that reforms are needed and offers a roadmap for improving culture. Culture is an attribute of a community, not an institution. Institutions’ policies, procedures, practices, and leadership creates and sustains the ethical culture for its activities. Sustaining an ethical culture for research with research participants will require institutional time and resources. More importantly, it will require personal commitments and an understanding that cultural reform is necessary if health research is to be able to keep its promise of creating better knowledge to serve human health.

**Specific Actions**

In addition to the principles put forth above, the following actions are designed to address recommendations 3.1.1 to 3.1.5 in the Leadership Initiatives section, and 3.6.1 to 3.6.3 in the Institutional Culture section of the External Review report.

- Create a document that explains the U of M’s commitment to research participant protection, including the ethical conduct of research involving research participants.
- The HRPP, IRB, OVPR, and AHC websites as well as departments that are involved in research with research participants, will incorporate clear statements, in a prominent location, about the U of M’s commitment to research participant protection, including the ethical conduct of research involving research participants. The statements will be written for audiences that include current and potential research participants, investigators conducting research with research participants; U of M faculty; the general public and others who are concerned with the U of M’s maintaining the highest ethical standards. In addition, there will be a one-stop web location that has easy-to-access consolidated information regarding IRB policies, educational materials and programs plus resources for getting advice and consultation on legal, regulatory, and ethics topics related to research participant protection.
• Statements and websites will be reviewed and discussed with a newly created Community Oversight Board described later in this report as well as the Research Compliance Advisory Committee (RCAC). The RCAC is a high level faculty advisory committee who provides guidance and consultation to the Vice President for Research on issues related to research risk and compliance.
• Future strategic plans for segments of the U of M that relate to research participant research will include statements on the U of M’s values as they relate to research participant protection.
• Planning for basic and advanced education of researchers conducting studies that use research participants will include the voice of research participants, research ethicists, and educators. Section 12 “Educating and Training of Investigators” has further details on including these voices.
• Educational opportunities on human research participant protections will include moderated discussions at department faculty meetings that will involve peer-to-peer education.
• The U of M will host a Campus Conversation or other forum on the topic of human research participant protection.
• The U of M will regularly benchmark itself against its peers to ensure that our human research participant protection programs meet or exceed the norm.

4. **IRB Membership**

*Covers External Review report recommendations: 3.2.1, 3.2.2, 3.2.3*

The External Review focused on the biomedical IRB and noted there were no comments made during interviews or findings in any of the documents reviewed that suggested there were problems in the performance of the Faculty Social/Behavioral IRB or the Student Social/Behavioral IRB. Currently, the U of M medical IRB has nine member slots with a requirement of five members for quorum. There is a pool of 37 potential members including physician scientists, other scientists, and non-science members. On average, an IRB member
attended only 6 of 26 meetings during the first half of 2014. This use of a “rolling roster” of members causes a lack of continuity and consistency by the IRB. Historically, at most meetings of the medical IRB there were only 5 to 7 members to handle large agendas. The External Review also noted that the expertise on the medical IRB did not sufficiently match the types and numbers of research protocols reviewed: there were no members from adult hematology, oncology, transplant, cardiology, surgery, or neurology although those specialties comprised over 300 protocols from October 1, 2013 through September 30, 2014.

The Implementation team agreed that major changes are required concerning the perception of service on the IRB, the composition of the IRB, and compensation for service on the IRB as noted in the following recommendations:

- **The U of M must promote measures to increase the value of service on the IRB**

To recruit U of M faculty to serve on the IRB, IRB service must be viewed as a valued activity. Among some faculty and in some departments at the U of M, the current culture is that IRB service is burdensome, unvalued, and to be avoided at all costs. This is in contrast with serving on or chairing an NIH study section, which is not only valued but encouraged and celebrated. Change will require the following: the President, the Provost, the Vice President for Research, the academic deans (including the Dean of the Medical School), and department chairs must make it clear that serving on an IRB is a service activity that is valued and encouraged; faculty members, when judging their peers for tenure and promotion should view IRB service as an important contribution. In addition, faculty, when considering whether to serve on the IRB, must recognize that reviewing studies for the IRB will improve their own scientific process of conducting human research using research participants, just as reviewing proposals for NIH improves their own proposals.

- **Increase the number of full IRB committees and limit the number of items on each agenda**
The Implementation team recommends increasing the number of full board medical IRBs from one to four, each with weekly two hour meetings. This would increase the number of biomedical meetings per month from five to 16 (and the hours of convened meetings to 32 hours per month) which should be sufficient to handle the workload. Each medical IRB should have at least 13 members with a quorum of seven members. The IRB staff should triage the agenda items such that the workload for each meeting can be completed in the allotted time. Each agenda could include new submissions, continuing reviews, modifications, and deferral responses. We also recommend that one of the full board biomedical IRBs have significant expertise in research with vulnerable research participants.

- **Increase number of IRB members**

Increasing the number of IRB members will require representation from departments and divisions that constitute the highest volume of reviewed protocols. Based on the number and type of reviewed protocols, each of the following departments and divisions should have one or more members on one or more of the four IRBs: Adult Hematology, Oncology, Transplant, Psychiatry, Cardiology, Surgery, Pediatric Hematology/Bone Marrow Transplant, Pediatric Endocrinology, and Neurology. In addition, faculty from the School of Nursing and nurses with research or clinical expertise in these areas should serve on the four IRBs. Board members on each medical IRB committee could also serve as alternates on the other medical IRBs to ensure an adequate pool of members to achieve quorum, to foster uniformity between the decisions of the four biomedical boards and to share the expertise of members between the boards. There will also be times when relevant scientific or human research participant expertise may not exist on the standing biomedical IRBs and will necessitate recruitment of other board members with special expertise that is either internal or external to the U of M. These members could include a geneticist, a prisoner representative, an ethicist, or a stem cell expert, each would serve on at least one committee and to serve as a resource for the other committees.
• **Compensate IRB board members**

The participation of members on all of the medical and non-medical IRBs is currently voluntary. The University of Minnesota uses different revenue sources for compensation that vary by school/department/college. Participation on the IRB is an extremely time consuming process, particularly for clinical faculty who must generate partial salary support from clinical service and research sources, and time devoted to IRB service decreases contributions to their salaries from other sources. The Implementation team recommends that clinical faculty board members who serve on all the medical and non-medical IRBs should be compensated by the U of M through the provision of salary support to their department or division to allow 10 percent protected time from other responsibilities to serve on the IRB. The Implementation team further recommends that non-clinical faculty who serve on medical or non-medical IRBs be compensated at an appropriate rate that will be determined before this plan is put into place. It is the expectation of the U of M leadership that the relevant department chairs, division leaders, and deans will embrace and enforce this process. IRB chairs should be compensated by providing salary support to their department or division to allow 25 percent protected time from other responsibilities to serve on the IRB. More community members should be recruited for the new medical boards and to reduce the work burden on each community member. Community members on all the medical and non-medical IRBs should be compensated $3-5K yearly, and also receive parking vouchers, and be invited to an appreciation dinner at least once yearly.

• **Establish requirements for attendance**

Board members should attend at least 60 percent of meetings and those with lower attendance will be asked to discontinue membership.

• **Facilitate use of central IRBs (CIRB) for human participant research**

Many granting organizations including the National Institutes of Health, the National Cancer Institute and some industry sponsors require oversight by a CIRB rather than
individual IRBs at participating research centers. The UMN supports the use of CIRBs as well as the opportunity to serve at the CIRB for some multicenter studies. In the future the use of CIRBs may reduce the workload for the UMN IRB and make it possible for cost-savings and a reduction in the need for some of the boards and some personnel.

5. **IRB Protocol Review Process**

*Covers External Review report recommendations: 3.2.4, 3.2.5, 3.2.6, 3.2.7*

The implementation team discussed several issues related to the IRB protocol review process in response to the External Review and Legislative Auditor’s reports. Concerns raised in those reports regarding inadequate documentation at committee meetings included: discussion of risk and benefits of participation for research participants; controverted issues; long turnaround times for review and meaningful details on nature of change and the rationale for changes made to protocols. The meeting agendas frequently had multiple items that did not require full committee review and the sheer volume of the agenda items brought into question the ability of the committee to have thoughtful discussion of all the items with the appropriate expertise at the table. There needs to be a balance in the agenda items that takes into account the complexity of the review or protocol, the number of items and the type or review required for a new application or a change in protocol. The effort to standardize meetings will lead, eventually, to more efficiency in review and allow for a turnaround time of two weeks (10 business days) for a review response from date of submission. Current and planned updating to forms allows for better communication during meetings.

Moving forward, IRB meetings will be conducted in a uniform format with focus on the regulatory requirement for approval. The criteria for approval will be discussed and any controverted issues will be voted on or noted. Stipulations that are identified by a reviewer will be associated with a specific criterion for approval. There have already been efforts made by the IRB staff to revise the format of the convened IRB meeting to include a meaningful summary of the study, documentation of discussion related to controverted issues, the resolution of controverted issues, and documentation to support the rationale of the
committee for requesting changes to the application and consent form. Consistent feedback on items should be sought from members and IRB staff at convened meetings. The IRB Assistant Director is present at convened meetings to educate, lead, and enforce these new guidelines.

The IRB will also have adequate administrative staff to provide pre-review of items to determine if it is necessary and required to bring them to full committee. This pre-review will decrease the number of items on an agenda. There already has been a great deal of work done to revise forms for application, reporting, and review to make the process more transparent and efficient. For example, there have been changes to the triage and review forms used by research compliance supervisors used in protocol reviews. Guidance and training needs to be developed and implemented for IRB staff to assure their expertise in the independent review and decisional capabilities on the need for full committee review. In addition, the adoption of an electronic IRB system will better facilitate communication and processes.

We recommend that some IRB staff and members conduct benchmark visits to other institutions to gather information and learn about best practices outside of the U of M. These benchmark visits will allow the opportunity to review forms and documents from other institutions as well as to observe IRB practices.

6. **Scientific Review of Studies**

*Covers External Review report recommendations: 3.3.10, 3.3.11, 3.3.12, 3.3.13, 3.3.14, 3.3.15, 3.3.16, 3.3.17*

Studies using research participants must undergo scientific review to ensure that the study has scientific validity and that the research procedures are appropriate for the study. That assurance is an integral part of the process that the IRB uses in its consideration of weighing the scientific knowledge that will be gained from the study against the risks for study participants.
UMN IRB Policy 904 covers scientific review. Under current policy, for studies involving minimal risk that are processed under expedited review, the scientific review is conducted by the IRB reviewer. For studies involving greater than minimal risk that are reviewed by the social and behavioral sciences IRB panels, the IRB members perform scientific review. For studies involving greater than minimal risk that are reviewed by the full biomedical IRB committee, scientific review must be done by independent peer reviewers, and researchers must provide documentation of that review.

IRB Policy 904 allows four methods for completing the independent peer review requirement:
1) Full peer review that is part of applying for funding to federal agencies such as NIH and NSF. 2) National non-federal agencies (e.g., March of Dimes) that use peer review as a part of their funding process. 3) Peer review done locally at the University of Minnesota. 4) Peer review facilitated by the University Human Research Protection Program (HRPP) and including review by a biostatistician.

Method 3 above has three options for peer review: (a) review by the U of M’s Cancer Protocol Review Committee (CPRC), (b) review of by Clinical and Translational Science Institute (CTSI) of their pilot funding awards, (c) Department peer review.

The External Review raised concerns that when Method 3c, departmental peer review, is employed, a number of issues exist including a lack of appropriate expertise of the peer reviewers, a failure to follow appropriate conflict of interest guidelines for peer reviewers (including when the peer reviewer is superior to or subordinate to the investigator), lack of sufficient detail in the review documentation, violations of the policy requiring a minimum of two reviewers, and insufficient documentation in IRB minutes that scientific review was adequately considered. The panel made eight recommendations related to scientific review. The action plan below addresses all eight of the recommendations.

In response to the External Review report recommendations, we will:
A. Eliminate Department Review

Method 3c, department review will be eliminated and that function will be combined into a new Method 4 called “HRPP Managed Scientific Review.”

B. Revise HRPP Managed Review Procedures

For the new “HRPP Managed Scientific Review” the review process will be revised according to the following:

1. The review criteria will appropriately combine what is now listed in IRB Policy 904 for review method 3c and review method 4.

2. Criteria will be developed for determining which studies require review by a biostatistician prior to the scientific assessment.

3. Peer reviewers:
   a. A minimum of two appropriately qualified experts will be required. The HRPP can require more than two reviewers if in their judgement scientific review would be aided by additional expertise. Reviewers can be from inside or outside the U of M.
   b. If the HRPP determines that a specialized reviewer is required from outside the U of M, the HRPP is authorized, on a limited basis, to provide an appropriate honorarium to that reviewer.
   c. Potential reviewers may be suggested by the investigator or may be suggested by the HRPP independently of the investigator. The HRPP, however, determines who will review and invites the reviewers.
   d. The names of the peer reviewers are not released to the investigator.
   e. Reviewer suggestions must come with a short statement of the expertise of the reviewer so that it is clear they are qualified to conduct a scientific review of the study in question.
f. Peer reviewers must have no real or perceived conflict of interest that would influence their work as reviewer. For the purpose of this review process, the definition of “conflict of interest” is, “Any situation that could cause a reasonable person with all the relevant facts to question the impartiality of the committee member or that leads a committee member to question his or her objectivity,” which is the definition used by NIH for reviewers participating in the review of NIH grant applications. Before reviewing the application, the reviewer must assert they have no conflict of interest related to the study in question.

g. Subordinates may not serve as a peer reviewer for a study where their immediate superior is a named investigator. For example, faculty may not peer review a study of their department head.

h. Those who have collaborated on a study with the investigator during the previous 12 months may not serve as a peer reviewer.

i. Other examples of conflict include: an investigator or member of the research team conducting the study; holds a financial interest in the business entity sponsoring the research; and could financially benefit from the results of the research (e.g., holds a key patent related to the research.)

4. Create a review form to be used by the peer reviewers. This form will replace the “ScientificReviewTemplate.doc” form and will require peer reviewers to address each point of the set of new criteria. The form should provide explicit instructions to the peer reviewer on how to conduct the peer review, much in the way that NIH provides instructions to reviewers of NIH grant applications.

5. HRPP staff will screen peer reviewer submissions for incomplete reviews, and work with the reviewer to complete an adequate review.

6. HRPP staff will not make any conclusions based on the peer reviews, but will organize and submit the required number of peer reviews to the IRB panel that is reviewing the study.
7. The investigator will receive the scientific reviews, with reviewer names deleted.

8. The HRPP managed review process could be done through the CTSI Clinical Translational Research Portal. However it is implemented, the process should have a single flow so that investigators are clear about the process.

9. Ideally, the goal is to provide a 10 day turnaround time on reviews.

The intent of this new process is not that the IRB panels conduct the scientific review, but rather that the HRPP manage the scientific review. The new process is intended to add no additional burden while at the same time ensuring that appropriate experts are performing the scientific review and that only those without conflict perform the review.

C. Revise IRB Panel Review Procedure

1. Add to the IRB meeting checklist an item to discuss the type of scientific review that occurred for the study being considered and whether the scientific reviewers had any concerns.

2. Document the IRB’s review of the scientific assessment documents in the IRB minutes.

D. Revise IRB Policy 904

Revise IRB Policy 904 to reflect the above changes.

7. Fairview University Research Oversight Committee

An oversight committee that can monitor the entire spectrum of clinical research across the Fairview health care system is essential. This committee would have the following charges: (1) ensure that both the research and clinical regulatory obligations of Fairview are met (2) ensure that research protocols conducted at Fairview are appropriate and feasible within the concurrent demands of patient care and (3) ensure that staff members at Fairview have a voice in the conduct of research at Fairview. The
committee will propose and approve policy and procedure changes, as needed, to achieve the charge. This oversight committee would include senior leader representatives from the Fairview Research Office, Fairview clinical staff, UM Physicians, University Academic Health Center and the University Office of the Vice President for Research. Convened meetings will occur quarterly with additional meetings if needed. The activities of the meetings will be posted on a website accessible to the research and clinical staff at Fairview and the U of M. Fairview staff, U of M faculty, and the public may contact this committee with concerns. Although this committee may need to address issues that arise with specific research studies that may impact policies and procedures, the FUROC will not function as a protocol review committee.

8. Monitoring of Studies

*Covers External Review report recommendations: 3.3.18, 3.3.19, 3.3.20, 3.3.21, 3.3.22, 3.3.23*

The most effective way to determine if clinical research studies are being performed as they should is to monitor them after IRB approval. There are currently two processes by which this monitoring occurs at the U of M: 1) the Post-Approval Review (PAR) program that reports to the IRB and OVPR and 2) the clinical trial monitoring service that reports to the Clinical and Translational Science Institute (CTSI) and the Academic Health Center.

As noted by the External Review, the PAR program may review, based on policy and procedures, any human subject research protocol reviewed by the IRB. This review is not equivalent to regular and ongoing monitoring of individual research protocols as described in the International Conference on Harmonisation Good Clinical Practice Guidelines (ICH GCP E6 5.18) that is generally conducted by the CTSI. Review by PAR is, generally, the review of the conduct of a protocol at a single point in time. The CTSI clinical trial monitoring service, however, is a service that is intended to assist U of M sponsor-investigators and conducts monitoring over the entire lifetime of the study. This assistance includes the above described GCP monitoring required by FDA regulations.
The External Review noted that post-approval monitoring has not effectively addressed concerns raised about research at Fairview and suggested that educational initiatives related to the functions of PAR may be warranted to promote greater awareness. The panel also observed that publication of policies about post-approval review, including the methods by which research protocols are selected, might also promote awareness of this program. Communication about PAR activities and results was a recurring theme in the External Review report. It was also suggested that the U of M consider the reporting relationship for the PAR function.

The Implementation team agreed that changes are required as noted in the proposed actions for each of the following action items:

- **Increase and expand PAR monitoring**
  
  It is recommended that results of PAR monitoring be reported to FUROC and the IRB. Fairview and the U of M would each disseminate information to their respective communities. In addition, at Fairview and UMP this reporting would extend to the clinical care functions as well as the research function. At the U of M, reporting would extend to the Office of Institutional Compliance. OVPR would prepare communication about findings for the community. Policies related to post-approval review, including information about risk-based selection of protocols for review, should be posted and available to the public.

  At the time of approval, the IRB shall determine if a protocol should be reviewed by the PAR during the first year of activity based on the anticipated risks of the study. In addition, the PAR will audit a sufficient number of other studies, as determined by statistical methods, to insure appropriate oversight of institutional research. A standardized evaluation is recommended that would identify compliance with protocol specified procedures and measures modified, if any, to enhance research participant safety. The newly created OVPR
Research Compliance Office should establish a process for monitoring follow-through on any recommendations for changes in study procedures.

- **Report PAR findings and IRB follow-up to department and school or college leadership**

The OVPR Research Compliance Office should provide information to department and school or college leadership about IRB follow-up to PAR reports. Reports to academic unit leaders and other institutional leaders should provide information about all PAR activities to share information about research that is well and properly performed as well as findings that require corrective action. Implicit in this recommendation is that the department and school or college leadership will be held accountable for making sure any corrective action is put in place in a reasonable time frame. Failure to do so could result in suspension of the further enrollment in the trial including suspension of the trial.

- **Perform live consent monitoring**

Live consent monitoring should be a part of this model with patient consent. The process would include: memorializing the interaction by recording, preferably by video; monitoring the process; and contributing to capacity assessment and consent via dialogue between the investigator and the consent monitor.

9. **For Cause Investigations**

*Covers External Review report recommendations: 3.2.8, 3.2.9, 3.2.10*

The External Review stated that “one of the most challenging but critical functions of an IRB is addressing incidents of researcher noncompliance” and noted that “in alignment with these federal regulatory requirements, the U of M’s IRB has policies and procedures to address noncompliance. The IRB policies not only address the requirement that researchers report incidents of noncompliance to the IRB, but also outline the IRB’s processes for handling the incident reports once received”. However, it was noted that “neither of the active
investigations to which it was privy during this evaluation had members with relevant expertise.” Further, the report noted external resources could have been used to help with the work of IRB investigation committees, but were not.

To address these issues, we propose the following:

- Place responsibility for these investigations in a newly created Research Compliance Office in the OVPR.
- The newly created Research Compliance Office in the OVPR will review and revise procedures related to the composition of the investigation panels to insure that membership includes members with relevant expertise.
- When a complaint is received, the complainant should promptly receive a response that includes information about what will happen next and a later response about the resolution.
- For a significant adverse event related to participation in a research study resulting in death, disability, or injury, the U of M must have a system for response to research participants and families that is prompt, empathetic, and informative. The principal investigator of the study must be an integral part of this process and should receive training on these types of discussions. This training should be incorporated into routine training for investigators.

10. **Human Research Participants Who Have Impaired or Fluctuating Capacity to Consent**

*Covers External Review report recommendations:*
- *Capacity to Consent* 3.4.1, 3.4.2, 3.4.3, 3.4.4
- *Vulnerability to Coercion* 3.4.5, 3.4.6
- *Longitudinal Assessment of Capacity* 3.4.7, 3.4.8
- *Legally Authorized Representatives* 3.4.9, 3.4.10
- *Use of Surrogate Consent* 3.4.11, 3.4.12
The policies and procedures described in this section of our report will create additional protections and inform best practices when proposed research involves adults who lack the ability to provide consent to participate in a study or whose ability to consent might wax and wane during the course of a study.¹

Capacity to Consent

Definitions:
Prospective research participants lack “consent capacity” (i.e., the ability to reflect on information about the experimental proposal and their experience of being a research participant) when they cannot make or express an informed choice to enroll or continue in a clinical trial in light of their understanding of the risks and benefits of the research and their own values.

All persons who are individually adjudicated or classified by law as “incompetent” shall be deemed to lack “consent capacity.”

Best practices shall refer to all aspects of this policy. Essentially it refers to a receptivity to considering new publications, research, and peer models for amending all aspects of the use of research participants insofar as such material is empirically validated and consonant with applicable laws and regulations.

General Considerations:
Impaired consent capacity occurs in a wide range of conditions and disease states. The IRBs should inform investigators that impaired consent capacity is not limited to specific disorders and provide a list of those conditions where impaired consent might exist.²


Consent capacity is task-specific both to the research proposal and to the complexity of decision-making required of the person considering consent to the study. Therefore, a judgment regarding an individual’s capacity to consent may not be the same for all research studies.

In many individuals, consent capacity is not static. A research participant’s consent capacity may improve, deteriorate or fluctuate during the course of a research study. Study protocols, consent forms and procedures should anticipate and address this phenomenon. Safeguards must in place prior to participant enrollment and, as appropriate, throughout the course of research participation.

**IRB Review Procedures:**

The IRB may determine that research that includes individuals who lack consent capacity may be accepted for research under the conditions that the research is likely to benefit persons with impaired capacity who are similarly situated with regard to benefiting from the medical knowledge to be gained by the research.

The IRB may accept that persons with mild impairments of decisional capacity (as defined by an instrument that has been validated for assessing the capacity to consent for research) may consent to research that is minimal risk and eligible for expedited review.

The IRB may approve any instance of greater than minimal risk research that is likely to benefit persons with impaired capacity who are similarly situated with regard to benefiting from the medical knowledge to be gained by the research provided such consent from persons with any decisional impairment results from the use of a Legally Authorized Representative to consent and give ongoing consent for the research participant. A Legally Authorized Representative (LAR) is defined as “an individual or judicial or other body authorized under applicable law to consent on behalf of a
prospective research participant to the research participant's participation in the procedure(s) involved in the research.” 45 CFR 46.102(c).

Policies, guidance, application and review forms, as well as the IRB review process should be reviewed and restructured for clarity and consistency to promote clear understanding and compliance with policies and procedures to assess and monitor capacity to consent. This review should align research participant screening or other protections with the degree of risk involved in a study or the level of risk of impairment in a targeted or enrolled population. This review should also promote strategies to enhance research participant decision-making, including the research participant’s ability to select a surrogate decision-maker in the event that the research participant loses decision making capacity during the course of the study.

IRB reviews should include a substantive assessment of the appropriateness of protocol-specific procedures addressing consent capacity in light of the research participant population being approached.

The IRB should devise means to verify decision-making capacity and to assess matters pertaining to vulnerability in all protocols.

Adults who lack consent capacity may not be the research participants of research when the research can be performed with research participants who possess consent capacity and the research is not directly relevant to investigating the disorder causing impaired consent capacity.

Studies involving greater than minimal risk but presenting the prospect of direct benefit to persons with impaired capacity may enroll adult research participants who lack consent capacity with at least the use of a LAR and in some cases an additional consent auditor.
Investigators and research staff who obtain consent should consider every potential research participant’s capacity to consent to the research. In studies where the recruitment of individuals with impaired consent capacity is not anticipated, the judgment that prospective participants have the capacity to consent to the research can ordinarily be made informally during routine interactions with the participant during the consent process.

**Planning Before the Study for Impaired Consent Capacity**

The method used to assess capacity, and when appropriate, the documentation of this assessment, should be tailored to the study population, the level of risk, and the likelihood of the involvement of participants with impaired consent capacity. An appropriate assessment tool, such as the tool developed by the University of Kentucky (or others listed in footnote 4 below), should be employed to assess capacity to consent before beginning the formal consent process.

Investigators and research staff responsible for the consent process and consent capacity determinations should be qualified and trained in the assessment of consent capacity, the difference between minimal risk and greater than minimal risk, the difference between competence and consent capacity and vulnerability, and the use of the chosen instrument used to assess consent capacity.³

When it is anticipated that the research might include individuals who have impaired consent capacity, researchers should assess prospective participants’ consent capacity and determine whether it is adequate to permit informed consent. The principal investigator must propose the use of an instrument that has been validated for

---
³ Definitions of minimal and greater than minimal risk and of competence and consent capacity are present in regulations. Minimal risk is the probability and magnitude of physical or psychological harm that is normally encountered in the daily lives, or in the routine medical, dental, or psychological examination of healthy persons (45 CFR 46.303(d)).
assessing the capacity to consent for research.\footnote{There is an increasing body of research validating ways to assess capacity for consenting to research. The use of validated instruments for assessing consent capacity for research should be considered evidence of best practices. The External Review included the current instrument developed by the University of Kentucky as an example.}

This determination should be documented in the research participant’s individual research record or case report form.

When it is anticipated that the research might enroll persons whose capacity to consent or revoke consent during the study may become impaired, researchers should devise a consent capacity monitoring plan to last for the duration of the study. Re-assessment of consent capacity will be based on risk, initial consent capacity, and the likelihood that the consent capacity might change over time. The plan should describe the steps to be taken (e.g., either seeking a legally authorized representative or discontinuing the research participant from the study) if consent capacity is lost while a study is underway.

\footnote{For example:
\begin{itemize}
  \item Rowbotham MC; Astin J; Greene K; Cummings SR. Interactive informed consent: randomized comparison with paper consents. \textit{PLoS ONE} \textbf{8}(3):e58603, 2013.
  \item Jeste DV; Palmer BW; Golshan S; Eyler LT; Dunn LB; Meeks T; Glorioso D; Fellows I; Kraemer H; Appelbaum PS. Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials. \textit{American Journal of Geriatric Psychiatry}. \textbf{16}(7):568-74, 2008 Jul.
\end{itemize}}

Screening devices for cognitive dysfunction (e.g., the Mini-mental State or SPMSQ) or for clinical decision making capacity (e.g., MacArthur Competency Assessment Tool (MACCAT) are less desirable than instruments that are validated for assessing research consent.
If a patient with consent capacity loses capacity during a study and remains enrolled under the consent of a Legally Authorized Representative or a prospectively established Durable Power of Attorney for that study, then IRB policies should specify the requirement for a plan to secure that research participant’s re-consent if capacity to consent is regained. The plan for this eventuality should be part of the original IRB proposal when fluctuations in consent capacity are expected to be common.

At the time of enrollment in the study, the research team should inform and encourage the research participant to designate an individual to serve as a legally authorized representative (LAR) or a durable power of attorney for their participation in the study. This representative will act in the event that consent capacity is lost during the study for that study only. Such delegation of authority may not be used for other research studies.

**Assessing Capacity to Consent and Obtaining Consent**

IRB will request that the consent process be witnessed and the form be completed by a person who is not also IRB approved study staff for the protocol, such as a UMP or Fairview nurse not associated with the research department or investigator. The IRB or the investigator may elect to have the consent interaction video recorded.

**During the Study**

When a research participant is found to have possibly lost consent capacity (either by the prospective monitoring plan or as an incidental finding by the research team, the person’s treating clinical treatment team, or feedback from family/friends), a Legally Authorized Representative must be engaged to evaluate the study and to either consent or withdraw consent to participation.

If the potential research participant revokes consent or assent at any time, then study participation must be put on hold. If the person reconsiders, there will be additional discussion with the advocate and a reconsent process.
**Legally Authorized Representatives**

The legally authorized representative (LAR) is understood in the sense of (45 CFR 46.111, 46.102(c) and 21 CFR 50.3(1)): “A legally authorized representative (LAR) is defined in both HHS and FDA regulations as an individual or judicial or other body authorized under applicable law to consent on behalf of a prospective research participant to the research participant's participation in the procedure(s) involved in the research.” However, the implementation team requests that the OVPR and the HRPP consult with the OHRP or the DHHS on current law pertaining to who may legally serve as a legally authorized representative to assure compliance and harmonization with applicable regulations and state and federal laws.

Current IRB policies 501, 506 and 703 must be reviewed and revised as needed. The IRB and HRPP will develop educational materials for LARs and investigators to explain the LAR role, authority, and considerations for making decisions. This information should be placed on the IRB webpage that includes “Guidance & FAQs” Adults Lacking Capacity or with Diminished Capacity to Consent” http://www.irb.UMN.edu/guidance/adults.html. This material must also describe all relevant federal regulations to investigators, and provide information about where further guidance can be found.

The investigator will be required to describe procedures that will be used to ensure the research participant’s LAR understands his or her obligation to represent the prospective research participant’s interests or values in consenting to the study or in consenting to remain in the study while it is underway.

The IRBs should review and provide approval for the inclusion of individuals who lack consent capacity as specified below:
Consent Advocate

The consent monitor could also serve as a consent advocate, including for studies that do not involve vulnerable research participants, if requested. All potential research participants will have access to an advocate at all times during consent discussions. The plan for ensuring that the consent advocate is made available will be identified in the IRB application review.

Conflicts of interest for potential consent advocates will be managed by the IRB. This may include a special panel of consent advocates or possibly ombudsmen or other options.

The consent advocate should perform consent monitoring. When fully implemented, this might include: assisting investigators in finding and using validated instruments to assess capacity and obtain informed consent, memorializing the consent, and monitoring the consent. Such a model would benefit from continuous quality improvement.

Research with Research Participants who are Vulnerable to Coercion or Exploitation

The aim of these recommendations is to create language that provides an understanding of additional protections and to inform best practices when proposed research involves adults who are vulnerable to coercion or exploitation that might influence their consent to research or their decision to continue in research.5

Definitions:

Vulnerable research participant are persons who are vulnerable to coerced participation in research. Vulnerability differs from impaired consent capacity in that it arises from the situational context and relationships of the potential research participant rather than from cognitive impairment. Furthermore, not every person of a vulnerable group is susceptible to coercion. Vulnerable research participants and persons from communities that are vulnerable and persons with characteristics that mark them as vulnerable deserve an equitable opportunity to participate as research participants. Research is necessary on vulnerable populations to enable them to benefit from biomedical research.

Vulnerable persons have consent capacity. Any person who lacks consent capacity or is adjudicated by law to be incompetent shall be fully covered by policies addressing that issue.

A complete list of examples of vulnerability is not possible. The list below suggests some situations where it may be relevant to research with research participants.

<table>
<thead>
<tr>
<th>Class of Vulnerability</th>
<th>Description</th>
<th>Example remedies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fear of Institutionalization as contingent on research participation</td>
<td>Potential subjects fear psychiatric or custodial or penal institutionalization</td>
<td>Research protocol and personnel should emphasize that no civil rights or procedural rights or treatment rights are tied to consent to research. Research should not have any role in the process pertaining to commitment or judicial determinations of competence. Clinical personnel who are engaged in competency hearings should not have any role in the research process.</td>
</tr>
<tr>
<td>Communicative Vulnerability</td>
<td>Potential subjects who are non-English speaking, sensory impaired, dyslexia, medical illiteracy or innumeracy</td>
<td>Medical translators, Translation and back translation of consent documents.</td>
</tr>
<tr>
<td>Institutional</td>
<td>Potential subjects who are</td>
<td>Students: when research participation is part of a</td>
</tr>
<tr>
<td>Vulnerability</td>
<td>Potential subjects who have an interest in the potential subject consenting to the study, e.g., persons in the armed forces, students or employees of the PI or academic health center.</td>
<td>class assignment, a time and effort equivalent alternative should be provided for those who do not wish not to consent. Course grades should not be based on consent. Data on research participation should not be available to the grading instructor until grades have been filed. Employees: work performance should not be based on research consent. Nursing home residents, day care students etc.: Participation in research should not determine access to special programming or basic services.</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Deferential Vulnerability</td>
<td>Potential subjects who are deferential because of informal hierarchies such as social class.</td>
<td>Care must be taken to emphasize choice and to minimize secondary consequences, e.g. loss of clinic care if the clinical trial is declined. <em>Not</em> all deferential behavior is subordinating. Some persons defer to their doctor’s expertise.</td>
</tr>
<tr>
<td>Medical Vulnerability</td>
<td>Potential subjects with health conditions for which there are no satisfactory standard treatments may have unreasonable expectations about the potential benefits or investigators may mislead them about risks and potential benefits.</td>
<td>Researchers must anticipate the <em>therapeutic misconception</em> in which potential subjects see research as benefitting them personally rather than benefitting persons in the future or that participating in an approved clinical trial implies benefit to risk ratio that is more favorable than conventional care. This is especially important in Phase I studies that are not designed to produce a therapeutic result. It is sound practice to separate the identities of the treating physician from the investigating physician so that treating physician can be a neutral sounding board for the patient’s questions. Their health care provider should explicitly tell patients that to decline research will not jeopardize their ongoing treatment.</td>
</tr>
<tr>
<td>Economic Vulnerability</td>
<td>Potential subjects who lack basic needs i.e., income, housing, or health care. Such persons may consent to research to meet these needs, which then may constitute an undue inducement.</td>
<td>Financial inducements for research should cover the time and expense of participation. Research which includes medical care, examinations, or social services can be more difficult and to the extent feasible such services should not be offered in a manner that is contingent on research participation.</td>
</tr>
</tbody>
</table>

The classes of vulnerable patients of pregnant women, children, and prisoners are covered by specific HHS regulations and will not be addressed here.
General Considerations

The IRB expects that principal investigators will:

- Demonstrate awareness of the nature of the vulnerability of research participants in the trial under consideration.

- Create procedures to avoid the coercion or exploitation of vulnerable persons by: ensuring that each potential subject understands that participation is voluntary, that to the extent feasible comparable health and social services will be available regardless of consent to participate in a clinical trial, that ensuring other people, including supervisors, in closed communities like schools, military units, prisons, or chronic care facilities will not know who in their institution has and who has not consented to participate in research.

- To avoid the risk of therapeutic misconception, protocols, and consent documents for studies in which treating caregivers are also investigators should contain a paragraph to note that the potential participant’s caregiver has dual responsibilities to both care for the patient and to conduct the research. The potential participant may request to see another caregiver to discuss treatment options before deciding to participate in the study.

The IRB will:

- Use internal reviewers (including consultants where necessary) who have the appropriate expertise to address the vulnerability of the research participants in the proposed study.

- Ensure that there are safeguards to protect the rights and welfare of vulnerable potential research participants.

- Record the nature of the vulnerability and any special protections required for research participants in its minutes and in communications to the principal investigators.

The IRB may require the use of independent consent monitors, particularly when the
treating physician is also the investigator, in order to minimize the possibility for undue influence or coercion.

11. **Department of Psychiatry**  
*Covers External Review report recommendations: 3.5.1, 3.5.2, 3.5.3, 3.5.4*

Department of Psychiatry research studies have raised particular concerns and criticisms including, but not limited to, the role of particular investigators, informed consent processes, IRB expertise in psychiatric research, and the role of Fairview staff’s involvement in protocol review, gatekeeping functions, and research monitoring. We see an opportunity to address concerns and create a culture of trust and transparency to enhance and support both clinical care and research within the whole of the U of M and Fairview.

The relevant parties include clinical investigators in the Department of Psychiatry and their study staff, IRB members who review psychiatric protocols, Fairview Research Administration staff, and M Health nurses, managers, and leaders as well as advocacy groups such as the National Alliance on Mental Illness (NAMI).

The overarching goal of our recommendations is to create a method for conducting clinical research in the University/Fairview health system that incorporates best research practices and a culture that is inclusive, built on shared values, and fosters trust between all participants listed above. To that end, we propose that CTSI accelerate the process for assuming management of interventional drug and device trials in the Department of Psychiatry. This had been under discussion for the past several months but a timeline had not been established. We recommend that CTSI work with Dr. Grabowski, Director of Research in the Department of Psychiatry to rapidly implement a plan where all activities related to project management and study coordination be transitioned to the CTSI. When the new chair of Psychiatry is identified CTSI will work with this individual to identify how they would like to have interventional drug and device trials managed. In addition, we recommend the actions described below:
Education

In coordination with Section 12 “Education and Training” of this report, the education recommendations are:

- To develop a culture of shared respect by creating and implementing an educational curriculum with cross-training of clinical staff, investigators, and IRB members on the ethics, mechanics, and importance of research. The training programs will be taught and facilitated by the CTSI in collaboration with the Center for Bioethics using methods and curriculum that has been reviewed, tested, and validated by the larger CTSA consortium and the HRPP.

- To require that any investigator and their research staff working with individuals who have impaired or fluctuating capacity to consent or who are vulnerable (as defined in section 9), will take additional training that is specific to clinical research with this population. As discussed in section 12, the curriculum could be developed and administered by the CTSI however content will be determined in collaboration by the HRPP, CTSI, Center for Bioethics and other U of M resources. This process should engage community members and include research participants.

- To form a specific IRB panel with specialized training on the unique needs of research with individuals who have impaired or fluctuating capacity to consent or who belong to vulnerable populations, and to ensure that all research with populations that meet this definition be evaluated by this panel. The curriculum provided to this panel could be coordinated by the CTSI but will include input from the IRB, Fairview psychiatrists, UMP, U psychiatry and psychology faculty, nurses, and bioethics faculty. We also recommend consideration of a pool of psychiatrists from other sites conducting clinical research who can serve as expert scientific consultants to the panel, providing reviews of protocols and independent assessment of capacity to consent of these individuals when necessary.
Enhancing a Culture of Mutual Trust for Clinical Care and to Foster Research

Climate Assessment

To better understand all aspects of the current clinical and research environment, an external expert will be engaged to determine the assets and liabilities in the current “climate” in which clinicians, researchers, and staff do their work. This assessment will involve how Fairview and UMP nurses, physicians, and staff members do their work. The climate assessment conducted through Fairview and UMP will inform the development of a plan to address areas of concern and achieve best practices to develop an environment of inclusion, shared values, trust, transparency, and integrity for psychiatric clinical care and research. Performance under the plan will be monitored to assure that the plan is meeting the desired goals and the climate is improving towards best practice. Confidential input through “hot lines” will be available to assure that all voices are heard. Responses to concerns will be made available according to the best practices identified. These could include postings on web sites and town hall meetings. The climate assessment will be repeated at intervals identified in the results of the initial assessment.

Creating a Culture of Inclusion

The proper conduct of a clinical research study requires input from all members of the research team at all stages of the study, including the clinical staff that is involved in recruitment or conduct of the protocol, and support of the research participant in the study. We propose developing a process where selected members of the clinical team (the non-research staff who provide standard of care for the participant) participate in all aspects of the protocol development and administration. This process includes participation in 1) protocol development to provide input on how the protocol will affect standard of care and 2) discussion of risks to the participant from the clinical perspective (such as drug-drug interactions, quality of life issues). The CTSI has an established process that can be used to evaluate the feasibility of a proposed protocol.
such as whether there is a population of eligible patients and appropriate resources), that could help facilitate this process. Appropriate members of the clinical team can be added to the feasibility assessment process and provide valuable input into the study design. On completion of the research project, a presentation will be made to staff to inform them of the results of the research.

**Fairview Health Care System Oversight**
We believe it is essential to create an oversight committee that can monitor the entire spectrum of clinical research across the Fairview health care system. The FUROC committee as proposed earlier in this report (see section 7 for full detail) will regularly monitor all of these activities and propose aggressive, innovative solutions to problems as they are identified. The charge to this team will include (but not be limited to) process improvement to remove barriers for research implementation while ensuring excellent clinical care, participant safety, ethical conduct of studies, and ensuring that research results are effectively communicated to participants.

**Enhanced Research Training and Oversight of Two Investigators in Department of Psychiatry**
The External Review recommended that because of ongoing concern and criticism, two investigators in the Department of Psychiatry specifically should receive supervision, coaching in leadership, and advanced training in human participant protections. Part of this will be dealt with by the methods described in section 13. In addition, these investigators will be required to review all of the publications and associated sets of information cited previously in the references of section 9. More enhanced post-approval review will be undertaken (on a bimonthly basis) to make sure that all clinical research protocols that these investigators participate in are proceeding appropriately. The OVPR is planning a national symposium on human research participant ethics and these two investigators will be required to participate in this activity. Finally, a plan for
leadership coaching of the two investigators will be developed and overseen by the Dean of the Medical School.

**Required Resources**

The required personnel and resources to implement this plan include professional coaches, external trainers, and potentially the support to create a new committee for protocol review, monitoring, and gatekeeping which requires personnel time and effort to make successful. All of these action items will require additional responsibilities for joint Fairview and U of M leadership, an OVPR Research Compliance Office and CTSI. Clinical and faculty experts will be needed on a case by case basis for protocol review, gatekeeping, and monitoring of studies through the new committee and subcommittees for investigative reviews.

12. **Engaging Research Participants**

*Covers External Review report recommendations: 3.3.24, 3.3.25, 3.3.26, 3.3.27, 3.3.28*

Although there are channels that exist for soliciting feedback from research participants, the External Review found that these were insufficient and require improvement. The External Review recommended that mechanisms be amplified, systematized, strengthened, and sustained for engaging and communicating with the research participant community. These mechanisms involve both soliciting and recognizing feedback and providing information on study outcomes.

The OVPR, HRPP, IRB, CTSI, Fairview Research Administration, investigators, research personnel, clinical staff, research participant family members, legally-authorized representatives, and the public play a crucial role in engaging with the research participant community.
Several approaches will be needed to fully engage with research participants, family members, and surrogate decision-makers in order to learn about their research experiences, and be responsive to any concerns shared or feedback provided. The CTSI’s Community Engagement Core could play a leading and coordinating role in developing community resources to advise and assist on soliciting research participant feedback. A new staff position in the CTSI Community Engagement Core, a community liaison officer, should be created to provide day-to-day management of the research subject engagement activities and to regularly report defined metrics to OVPR. The Community Oversight Board (see Section 15) also has a vital role including providing input into the communication processes developed, monitoring their implementation, evaluating their outcomes, and providing recommendations on strategies for improving the research participant experiences, including addressing concerns and providing recognition and feedback for concerns raised.

Specific approaches for increasing communication with research participants, their family members and their legally-authorized representatives include:

- Create a research participant satisfaction survey that is distributed to research participants and surrogate decision-makers to evaluate their research experiences. (The CTSI is currently piloting a standardized process to regularly solicit research participant feedback about their research experiences.)
- Develop procedures for collecting, analyzing, and reporting results from the research participant satisfaction surveys, including a sampling procedure developed in consultation with a statistician.
- Revise IRB application forms to include a section for expressing appreciation for participation and sharing final results with research participants; if there is no plan for sharing final results, this should be justified.
- Develop and post on the HRPP website a list of best practices for expressing appreciation for research participation and sharing final results with research participants (e.g., letter, newsletter, research website, departmental website, etc.).
• Incorporate monitoring of distribution of materials related to research participant reporting and implementation of plans to express research appreciation in IRB annual and final reports, along with any deviations.

• Create and broadly publicize policy and procedures for handling concerns about research from research participants, family members, legally-authorized representatives, research personnel, and clinical staff.

• Create and broadly publicize mechanisms for potential, current, and past research participants, family members, and LAR to provide confidential feedback and/or report concerns about the research process (e.g., toll-free telephone number, website).

• Create a mechanism for promptly addressing all reported research concerns and notify the reporter when the matter has been fully addressed.

• Develop and require investigators to distribute a handout (such as a small card) at study enrollment to research participants, family members, and LAR regarding where and how to provide confidential feedback or share concerns about the research procedures, including the mechanism for handling reported concerns. This is in addition to information provided on the informed consent form.

• Establish a process for reporting results to individual research participants when practical and when the participant has indicated they would like to receive study results. This process may vary from study to study because of differences in study design. For example online survey studies may be anonymous and feedback would be impossible or studies requiring samples to identify molecular mechanisms of disease may not yield results that can be easily translated to the non-scientific community.

The CTSI Community Engagement Core could develop and implement this plan, including the hiring of a community liaison officer (new position) who can develop materials, monitor channels of communication, and respond to research participants’ concerns. The Community Oversight Board will provide input on the policy, procedures, surveys, and educational materials, and strategies relevant to research participant engagement, monitor all complaints or concerns reported and their resolution. The OVPR’s newly created Research Compliance
Office should provide independent oversight of the research participant satisfaction surveys and reported research concerns and should provide oversight for the plan outlined here. Additional staff and IT infrastructure will be needed to fully implement this plan, including monitoring its implementation and summarizing results on a regular basis. In addition, researchers and research personnel will now need to distribute handouts and satisfaction surveys.

13. **Education and Training of Investigators**

*Covers External Review report recommendations: 3.3.1, 3.3.2, 3.3.3, 3.3.4, 3.3.5, 3.3.6, 3.3.7, 3.3.8, 3.3.9*

The report from the External Review stated that “It is essential that individuals at all levels of the human subjects research protections program be knowledgeable about the ethical principles, as well as the specific regulatory, policy, and procedural requirements related to human subjects research” and “while some improvements have already been implemented (or are in the process of being implemented) in the area of basic research participants protection training, it is critical that training in research participant protections not fall prey to “right size” educational requirements in the wake of ongoing institutional efforts to reduce the administrative burden placed on researchers”⁶. Several recommendations are advanced that mandate advanced training in research participant research protection, especially where study procedures are noncompliant with HHRP policies and procedures and in studies that involve vulnerable populations and/or those with limited decision making capacity. Those most impacted by the proposed changes include investigators, Center for Bioethics, AHC schools, Bioengineering, CTSI, IRB, individual departments, Fairview Research Staff, and research participants.

---

More effective, in-depth, reinforced, and refresher training opportunities for investigators and research personnel will improve the quality of ethical clinical research, and will provide enhanced safeguards and greater clarity to potential or active research participants. It is recognized that numerous bodies all have efforts directed toward research and research ethics training at the U of M, including the HRPP, CTSI, and individual departments, schools, and centers. While broad educational opportunities remain of value and numerous training venues expand access and opportunity, a dis-coordinated training platform can leave gaps in content and, hence, gaps in investigator and research staff comprehension of the most important principles in research participant protection and research compliance. To that end the team adopted the following solutions to the recommendations made by the External Review panel.

- Create a new position of a Human Research Procedures, Policies and Ethics Education Coordinator within the CTSI with links to the Center for Biomedical Ethics. The education coordinator will be responsible for establishing guidelines for basic and advanced research compliance and research participant protection training that is reviewed and approved by an oversight process in the HRPP. The education coordinator will ensure that both required and optional training modules are available and kept current.

- Provide clear expectations and education for documenting the education of investigators and their teams with respect to RCR, HIPAA, GCP, and CITI training.

- Conduct an evaluation of the educational resources of the HRPP, schools, departments, and divisions in the AHC, CTSI, and the Center for Biomedical Ethics specifically dedicated to the education and training of the research community to ensure that appropriate resources are in place to offer basic and advanced training opportunities in research participant protections.

- Provide appropriate training opportunities for all personnel working with vulnerable populations and mandate it be completed before the study can begin. It is important to note that CTSI can be an effective partner by supplementing the NCATS endorsed training in best clinical practices (GCP) with appropriate content on these issues that reaches the entire translational and clinical research workforce.
Design a coordinated plan for delivery of research participant protection updates that could involve newsletters, websites or presentations prepared for department, division, center or other academic unit investigator meetings.

Address mandated requirements for advanced training including content prepared or presented by the Center for Biomedical Ethics that will specifically address research in vulnerable populations.

Supplement current requirements for minimal training to initiate research involving research participants with both required and recommended advanced refresher training that should be promoted by departments, divisions, centers and other academic units by recommending that these topics be included in regular faculty, investigator and research staff meetings.

Provide easier access to training tailored to different research topics: social behavioral studies, observational or epidemiologic studies, therapeutic intervention studies, studies on vulnerable research participants, or those with diminished capacity to consent. Topics on HRPP policies and procedures should be included.

Engage the community on relevant research related committees, task forces, and educational programs to help researchers, research staff, research administrators, and U of M leadership form relationships with community stakeholders and thus more directly solicit their input on community priorities and areas of community concern. This can be facilitated by the CTSI Community Engagement Core which regularly and successfully engages in such activities.

14. **Accountability Metrics**

The implementation team has made several recommendations to further advance the Human Subjects Protection Program and the U of M research community. As part of implementing the recommendations, metrics will need to be established and collected to assure that the changes made are meeting the expectations of research participants, the U of M community, and our partners. Metrics can also allow for continued quality improvement with the expectation that
they will be reviewed at minimum twice each year by the Community Advisory Board and the newly created OVPR Research Compliance office.

The following are metrics to consider and correspond to each of the recommendation categories:

**IRB Membership:** Data will be maintained so that departmental and specialty representation are identified. Meeting attendance of members will be tracked to assess the representation at meetings and confirm that they are meeting expectations of commitment to membership. Compensation models for members will be defined and tracked.

**IRB Protocol Review Process:** Data will be tracked on the number and type of review (new application, change in protocol, response to deferral, report, protocol review time) that are on each convened IRB meeting agenda. The number present and role of members at convened meetings will be tracked. In order to assure equal and appropriate distribution of expedited reviews, the reviews will be tracked by the member to whom they were distributed. Use of expert consultation to inform review (either expedited or full committee) will be documented and tracked. Turnaround time from protocol submission to IRB review response will be tracked.

**Scientific Review:** For all biomedical applications determined to be greater than minimal risk, the method of scientific review will be captured. This will include those methods defined and agreed on by this document. For those undergoing review by the HRPP mechanism the following data will be captured: the type of protocol defined by specialty and funding; the number of individuals that complete the review; the specialty of the reviewer; the number that recuse themselves from review; the outcome of the review; communication from the reviewer about concerns.

**Monitoring of Studies:** It is anticipated that this activity will increase as staffing levels increase in the IRB. The number of staff required for review will be tracked. The number of reviews and the reason for the reviews, for cause or random, will be captured. There will be comprehensive communication of findings. There will be a mechanism for the IRB to do quarterly reports of generalizable findings to the research community for education and compliance. There will be
more consistent communication of follow-up with research teams and our partners, including Fairview and Gillette.

**For Cause Investigations:** This activity will be moving into a newly created Research Compliance Office in OVPR. The number of investigations will be tracked. The number of individuals required to do the investigation will be captured. The outcome of the investigation will be communicated in generalizable terms for the education of the research community.

**Research with Vulnerable Populations:** The following data will be captured: who performed the consent (research coordinator or investigator); who signed the consent (research participant, single parent, both parents, guardian, LAR); if an advocate participated in the consent process and signed the document. For specific protocols, at study initiation, there will be a plan established for timed prompts to investigators to have them consider re-evaluation of capacity of consent for research participants for the duration of the study. The newly created OVPR Research Compliance Office can review this data and target studies that may be appropriate for post-approval review. Tracking the inclusion of adults with diminished or fluctuating capacity as part of the application process will occur.

**Department of Psychiatry:** Because we are recommending that interventional drug and device trials in the Department of Psychiatry are managed by the CTSI, we also recommend that for these trials, the CTSI conduct all routine monitoring for those studies. Metrics will be collected on the management of protocols in the department. Examples of this include: training of Department of Psychiatry investigators; time of presentation of protocol to FUROC; number of revisions to Department of Psychiatry protocols; number of events of significance identified by PAR program; number of findings on OVPR Research Compliance Office reviews; number of people who leave the trial; and number of inquiries or full investigations.

**Engaging Research Participants:** The creation and broad publicity of policy and procedures for handling concerns about research from potential, current, and past research participants, family members, legally-authorized representatives, research personnel, and clinical staff to provide confidential feedback and/or report concerns about the research process (e.g., toll-free telephone number, website), will be monitored. The creation of a handout (such as a small
card) at study enrollment to research participants/family members/legally-authorized representatives regarding where and how to provide confidential feedback or share concerns about the research procedures, including the mechanism for handling reported concerns (Note: this is in addition to information provided on the informed consent form), will be monitored and quantified. Feedback from a newly created research participant satisfaction survey using procedures for collecting, analyzing, and reporting results from such surveys will also be analyzed. Materials will be distributed related to research participant reporting and implementation of plans to express research appreciation in IRB annual and final reports.

**Education and Training of Investigators:** Currently these data are collected by automatic reporting to the U of M upon completion of a class or by self-reporting. With the enhanced number of opportunities for education and training, CTSI and HRPP’s capabilities in this area should be employed to track the necessary metrics regarding training and education of clinical research investigators.

**Managing Conflict of Interests:** This will be continued to be managed by the U of M mechanisms that are already in place and as described in section 15.

The Implementation team is charged with improving the U of M environment for clinical research and allowing for improved protection of research participants. Effective and meaningful data capture is critical for this mission. This collection, interpretation and dissemination of accountability metrics will require technical expertise and personnel to implement these recommendations. Appropriately resourcing this effort will ensure that proposed changes are followed and the outcome of these changes is measured. All stakeholders should be kept appropriately informed.

15. **Managing Conflicts of Interest**

The University of Minnesota encourages the collaboration of UMN investigators with industry for the discovery and development of new technologies and therapies. At the same time, we recognize the importance of disclosing and managing real and perceived conflicts of interest
when such research is undertaken. The purpose of this section is to identify and manage through the process of open disclosure and review, conflicts of interest between an investigator’s research project obligations and their private interests and obligations. The policies described in this section would apply to all internally or externally funded research involving humans, animals, biospecimens and all other research requiring IRB approval. The current UMN procedure for evaluating interests and managing conflicts of interest is available at:

http://www.policy.UMN.edu/Policies/Operations/Compliance/CONFLICTINTEREST_PROC02.html

The new policies we recommend are consistent with Public Health Service (PHS) regulations, “Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective Contractors,” 42CFR, Part 50, Subpart F and 45 CFR, Part 94, effective August 24, 2012. Because we are suggesting a change in UMN policy, it will need approval by the normal UMN policy process, including review by faculty governance.

We recommend that the University of Minnesota adopt a more stringent reporting structure than dictated by current UMN policy or PHS guidelines. We propose that henceforth, for all human research studies, a financial interest, including equity, consulting income, speaker fees or royalties, must be disclosed from the first dollar or from contractual rights to receive funds for the study. In addition, we recommend that an investigator not receive any personal income from consulting or for honoraria for speaking or participating in meetings from a company during the time that investigator participates in any research study funded by that industry sponsor. The investigator may receive reimbursements for travel, salary support for effort committed for performing the research, and other study related expenses as approved in the research budget. With approval of the Conflict of Interest Review Panel, an investigator may concurrently consult for a company and conduct research sponsored by that company if the payments for the consulting are directed by the company to the U of M and not to the investigator.
While the new policy will prohibit personal compensation, some exceptions may be allowed. The case for an exception may be made by the investigator and will be reviewed by the IRB and by the Conflict of Interest Review Panel. To proceed, the exception must be approved by both entities, and a conflict management plan must be in place before the study can proceed. Some, but not all, examples of possible exceptions include the following:

1. An investigator who has intellectual property that has been licensed to a company and the investigator wishes to conduct research by the company, assuming the research does not add financial value to the intellectual property. This might arise if the research is on a drug or device not covered by the intellectual property owned by the investigator.

2. An investigator has a study in which the participants have come off the study, the primary paper is published but the study is still open with the IRB to allow for continued data analysis not directly related to the study drug.

16. **Community Oversight Board**

The External Review and the Legislative Auditor report noted that there were insufficient channels of communication to change public perception of research oversight. President Kaler’s letter (3/18/15) to the Legislative Auditor and the subsequent Board of Regents’ resolution (3/27/15), call for a Community Oversight Board (COB) to be established to ensure that the U of M is using best practices in the protection of research participants.

The COB will be composed of external academic, professional, and community experts in human research participant research ethics, with special emphasis in the area of interacting with individuals with diminished mental capacity. The purposes of the COB will be to: 1) protect community interests and ensure community benefit from research conducted at the U of M; 2) provide input on policies, procedures, research participant and surrogate decision-
maker education, and activities designed to solicit community engagement with understanding of research; and 3) critique U of M communications and recommend dissemination strategies related to research ethics and research participant protection; The COB will help to build and foster trust and mutual understanding of research values, culture, and research participant protection, including the development of communication strategies for use within and outside the U of M.

The composition of the COB will include 12 members including external experts in research participant protection programs, ethicists, research participants, surrogate decision-makers/legally authorized representatives, research advocates, community leaders, and service providers from community-based, non-governmental organizations from diverse profiles (e.g., race, ethnicity, gender, age, disability, and socioeconomic status), experiences, and expertise. Members who have professional or personal experience with human participant research will be selected so that representation will cover a broad range of topics and vulnerable populations, including those with impaired decision-making capacity.

COB external members may include:

- Director of a human subjects protection program that is nationally renowned for its excellence
- An expert in the protection of vulnerable populations, including those with impaired decision-making capacity
- Ethicist whose expertise is in human research participants protection
- Clinical research investigator
- Several past or current participants in greater than minimal risk research studies at the University of Minnesota or other institutions.
- One or more family members and/or surrogate decision-makers/legally authorized representatives whose family member has participated in research
- Research coordinator involved in studies with vulnerable populations
● Research or patient advocate (e.g., representative from the National Alliance of the Mentally Ill or similar type of organization)
● Community leader (e.g., advocate for dealing with health disparities and provision of health care and other services to marginalized and vulnerable populations)
● Service provider involved in care of vulnerable patients

The chair of the COB will be appointed by the Vice President for Research and will be an external expert in human participant protection. The COB will report regularly to the Vice President for Research.

The COB will convene within one month of appointment. The chair will determine a meeting schedule and procedures. Administrative support and reimbursement of expenses will be provided by the U of M. The U of M will provide administrative support, reimbursement of expenses, and honoraria for COB members for whom participation on the COB does not fall within their professional responsibilities.

Responsibilities of the COB will include:

● Advising the Vice President for Research on best practices for human research participant research, community norms and expectations
● Providing input on topics related to research ethics, culture, and education (researchers, research participants/surrogates), and strategies for integrating research participant protection into practice.
● Providing feedback related to U of M messaging and communication strategies about human research and research protection.
● Advising the Human Research Protection Program (HRPP) on the development of policies and procedures related to the development of informed consent forms/processes, recruitment materials and other study-related documents, and strategies for soliciting feedback from the broader community and research participants.
• Advising the HRPP on best practice methods for disseminating research findings and other reports to the community.

• Suggesting strategies to address ethical and operational aspects of study conduct with vulnerable populations, including those with impaired decision-making.

• Informing the HRPP about information, misinformation, or rumors circulating in the community and concerns from the community and research participants/surrogate decision-makers.

• Advising how to address negative research experiences with the community.

• Helping build trust with the community by conveying information about research to the community.

• Completing research ethics and other required training and providing feedback on that training and suggestions for its improvement.

• Assisting in the dissemination of COB results and activities to appropriate audiences.

17. **External Advisor**

The charge to the Implementation team included engaging an external advisor with deep knowledge in human subject protection programs, regulations and law to work with the U of M on implementation of the recommendations of the Implementation team. We recommend engaging an external advisor as described and will do so once the report of the Implementation team is formally adopted by the U of M Board of Regents.

We will identify and retain an individual who is considered an international expert in the area of human participant research. We may start by re-engaging one of the members of the External Review, and if this is not possible, identify an expert in this area based on academic scholarship, practice and international reputation. This person will be provided with a copy of the Implementation team report and will work with the individuals named in section 7 to advise on implementation strategies and provide input and feedback to the Vice President for Research and Vice President for Health Sciences about the progress of the implementation process. It is
expected that this person would engage on a monthly basis until the implementation is complete.

It is important to note that the HRPP program will also be receiving substantial input into its future structure, philosophies, policies and procedures from those who comment on this report and from the June 2015 accreditation site visit by the American Association of Human Research Protection Programs (AAHRPP).
18. **Post-Report Activities**

We have listed those individuals who could be assigned responsibility for implementing the actions that fall under each section of the report. These assignments include both faculty and administrative key stakeholders.

<table>
<thead>
<tr>
<th>Above Section #</th>
<th>Assigned Individual(s)</th>
<th>External Report Recommendation/Implementation team Action Plan Number</th>
<th>Implementation Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>1)</td>
<td>Tremaine, Herman, Jackson</td>
<td>N/A Exec Summary</td>
<td>N/A</td>
</tr>
<tr>
<td>2)</td>
<td>Implementation team</td>
<td>N/A Process</td>
<td>N/A</td>
</tr>
<tr>
<td>3)</td>
<td>Jackson, Herman, Schacker/CTSI, Deans, Department Chairs, President, Provost, BOR</td>
<td>3.1.1, 3.1.2, 3.1.3, 3.1.4, 3.1.5, and 3.6.1, 3.6.2, 3.6.3</td>
<td>6-12 months</td>
</tr>
<tr>
<td>4)</td>
<td>Dykhuis, Billings, Biros, Jackson, Herman, Wyman</td>
<td>3.2.1, 3.2.2, 3.2.3</td>
<td>3-6 months</td>
</tr>
<tr>
<td>5)</td>
<td>Dykhuis, Billings, Biros, Schacker/CTSI, Herman, Studham, Jackson</td>
<td>3.2.4, 3.2.5, 3.2.6, 3.2.7</td>
<td>6-12 months (exception: electronic IRB scheduled implementation 2017)</td>
</tr>
<tr>
<td>6)</td>
<td>Dykhuis, Billings, Biros, Jackson, Herman, Schacker/CTSI,</td>
<td>3.3.10, 3.3.11, 3.3.12, 3.3.13, 3.3.14, 3.3.15, 3.3.16, 3.3.17</td>
<td>6-9 months</td>
</tr>
<tr>
<td>7)</td>
<td>Herman, Jackson, Wilson</td>
<td>N/A FUROC</td>
<td>3-6 months</td>
</tr>
<tr>
<td>8)</td>
<td>Herman, Jackson, Schacker/CTSI, Dykhuis, Wilson, Department Chairs, Internal Audit</td>
<td>3.3.18, 3.3.19, 3.3.20, 3.3.21, 3.3.22, 3.3.23</td>
<td>6-12 months</td>
</tr>
<tr>
<td>9)</td>
<td>Herman, Waldemar</td>
<td>3.2.8, 3.2.9, 3.2.10</td>
<td>3-6 months</td>
</tr>
<tr>
<td>10)</td>
<td>Miles/Bioethics, Scheman, Wyman, Billings, CTSI, Dykhuis</td>
<td>Capacity to Consent 3.4.1, 3.4.2, 3.4.3, 3.4.4 Vulnerability to Coercion 3.4.5, 3.4.6 Longitudinal Assessment of Capacity 3.4.7, 3.4.8 Legally Authorized Representatives 3.4.9, 3.4.10 Use of Surrogate Consent 3.4.11, 3.4.12</td>
<td>6-12 months</td>
</tr>
<tr>
<td>11)</td>
<td>Jackson, Wilson, Paller, Ext. Advisor</td>
<td>3.5.1, 3.5.2, 3.5.3, 3.5.4</td>
<td>6-12 months</td>
</tr>
<tr>
<td>12)</td>
<td>Waldemar, Dykhuis, Billings,</td>
<td>3.3.24, 3.3.25, 3.3.26,</td>
<td>6-12 months</td>
</tr>
</tbody>
</table>
19. Analysis of Resources Required for Implementation

<table>
<thead>
<tr>
<th>Resource Description and Estimated Cost</th>
<th>Resource Responsibility/Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Paid IRB member salaries (10% effort), Co-Chairs 25%</td>
<td>IRB</td>
</tr>
<tr>
<td>- 50 faculty avg. salary $150K annual- $750,000 annual; co-chairs- 75,000 annual- total- $825,000 recurrent; community members (at least 12) each 3-5 K yearly.</td>
<td></td>
</tr>
<tr>
<td>2. Additional Internal PAR monitors (3 additional FTE)</td>
<td>IRB</td>
</tr>
<tr>
<td>- $100k (salary plus benefits)- $300,000 recurrent</td>
<td></td>
</tr>
<tr>
<td>3. Paid scientific review activities</td>
<td>IRB</td>
</tr>
<tr>
<td>- Assume $100/protocol; 5,000 protocols/year- $500,000 recurrent</td>
<td></td>
</tr>
<tr>
<td>4. Additional IRB administrative staff (2FTE?)</td>
<td>IRB</td>
</tr>
<tr>
<td>- $200,000 recurrent</td>
<td></td>
</tr>
<tr>
<td>5. Media culture campaign staff (1FTE staff?)</td>
<td>OVPR</td>
</tr>
<tr>
<td>- $100,000 one time</td>
<td></td>
</tr>
<tr>
<td>6. HSP training staff (1 FTE?)</td>
<td>CTSI</td>
</tr>
<tr>
<td>- $100,000 recurrent</td>
<td></td>
</tr>
<tr>
<td>7. Community Oversight Board staff (0.5 FTE)</td>
<td>OVPR</td>
</tr>
<tr>
<td>- $50,000 recurrent</td>
<td></td>
</tr>
<tr>
<td>8. Additional IRB staff (2 FTE)</td>
<td>IRB</td>
</tr>
<tr>
<td>- $200,000 recurrent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Description</td>
</tr>
<tr>
<td>---</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>9</td>
<td>External Advisor on implementation</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>External consultant for Dept. of Psychiatry implementation culture change</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Co-review by PAR and an external IRB of protocols that involve decisionally</td>
</tr>
<tr>
<td></td>
<td>impaired research participants.-</td>
</tr>
<tr>
<td>12</td>
<td>eIRB- electronic IRB system</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Chesapeake IRB audit review of 100 random protocols.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Community liaison officer – 1 FTE</td>
</tr>
<tr>
<td>15</td>
<td>CTSI management of psychiatry studies – unknown until audit of current</td>
</tr>
<tr>
<td></td>
<td>trials and feasibility assessment completed.</td>
</tr>
<tr>
<td></td>
<td><strong>TOTALS:</strong></td>
</tr>
<tr>
<td></td>
<td>One-time costs: $5,450,000</td>
</tr>
<tr>
<td></td>
<td>Recurring: $2,237,500 (additional to current $2,182,123 base budget) = total</td>
</tr>
</tbody>
</table>

Another way to calculate the needs of the HRPP program is by median budget per protocol managed. Programs with volumes similar to ours (> 4,000) average $607/protocol. Last year we had 5,814 protocols which results in recurring budget of $3,529,098. The current HRPP budget is $2,182,123.
20. Conclusion

The External Review identified cultural and procedural shortcomings in the Human Research Protection Program (HRPP) at the U of M. In this report, the implementation team has addressed those deficiencies with a comprehensive plan that includes disruptive changes to transform the culture and improve multiple processes. Currently, the HRPP has many positive attributes, including policies and procedures that uniformly align with regulations, certification by the Association for the Accreditation of Human Research Protection Programs, and a past history of excellence. The current plan will help preserve what is good about this program and restore confidence and pride in the human research endeavor, collegiality among the research community, and will better ensure the safety of human research participants and scientific excellence.
21. Appendices

21.1. Advancing Human Subjects Research Organizational Chart

- **Protocols**
  - Psychiatry Study
  - Pre-Approval Process (optional for others)

- **CTSI**
  - Scientific review by Federal Agency or Cancer Center

- **Scientific Review at IRB**
  - Vulnerable or Impaired population?

- **Medical IRB panels**
  - Medical IRB panel with vulnerable population emphasis

- **IRB**
  - Scientific Review
21.3. List of External Review Recommendations

The following is the list of recommendations from the February 23, 2015 report of the External Review. The recommendation number is the number assigned to a recommendation in our report.

<table>
<thead>
<tr>
<th>No.</th>
<th>Report Section</th>
<th>External Review Page</th>
<th>External Review Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1.1</td>
<td>Leadership Initiatives</td>
<td>20</td>
<td>Publicize unequivocal statements on the administration’s intention to create and nurture a culture of ethics in research; the OVPR must then animate these values to life by investing in their visibility and adoption at all levels of the University’s research enterprise.</td>
</tr>
<tr>
<td>3.1.2</td>
<td>Leadership Initiatives</td>
<td>20</td>
<td>Convene a task force that would include research participants, research ethicists, educators, researchers, and HRPP/IRB staff to consider ways in which ethics and ethics education on the topics of research participant protections will be integrated into practice.</td>
</tr>
<tr>
<td>3.1.3</td>
<td>Leadership Initiatives</td>
<td>20</td>
<td>Explore ways in which an acknowledgement of the primacy of research participant protections and ethical research could be integrated into relevant University publications, materials, and web pages.</td>
</tr>
<tr>
<td>3.1.4</td>
<td>Leadership Initiatives</td>
<td>21</td>
<td>Incorporate the University’s stated commitment to, and plans for strengthening, research ethics and research participant protections in future strategic planning.</td>
</tr>
<tr>
<td>3.1.5</td>
<td>Leadership Initiatives</td>
<td>21</td>
<td>Require all departments engaged in clinical research to acknowledge this refocusing of University research priorities and craft statements reflecting their own commitment to excellence and accountability in human subjects protections.</td>
</tr>
<tr>
<td>3.2.1</td>
<td>IRB Membership</td>
<td>27</td>
<td>Implement guidelines regarding IRB meeting attendance in order to ensure that a larger, more critical mass of members are present at each meeting.</td>
</tr>
<tr>
<td>3.2.2</td>
<td>IRB Membership</td>
<td>27</td>
<td>Broaden the membership of the Medical IRB to ensure that it includes individuals with expertise reflecting the nature and volume of the University’s research.</td>
</tr>
<tr>
<td>3.2.3</td>
<td>IRB Membership</td>
<td>27</td>
<td>Consider providing compensation, or alternate incentives (e.g., released teaching time, reduction of other responsibilities, consideration during promotion, etc.) to foster and support qualified faculty participation on an IRB.</td>
</tr>
<tr>
<td>3.2.4</td>
<td>IRB Review Process</td>
<td>30</td>
<td>Revise the format of the convened IRB meeting minutes to include a meaningful summary of the study, any controverted issues that are discussed, their resolution, and documentation to support the IRB’s rationale for requesting modifications to the study</td>
</tr>
<tr>
<td>3.2.5</td>
<td>IRB Review Process</td>
<td>30</td>
<td>Consider whether certain actions may not warrant convened IRB review and therefore may not require discussion at the convened IRB meeting, freeing up time for the discussion of more complex and challenging protocols.</td>
</tr>
<tr>
<td>3.2.6</td>
<td>IRB Review Process</td>
<td>30</td>
<td>Consider developing a system for evaluating the appropriate number of action items per convened meeting agenda with consideration of the expertise of those present and the planned length of the agendas.</td>
</tr>
<tr>
<td>3.2.7</td>
<td>IRB Review Process</td>
<td>31</td>
<td>Consider making arrangements for the University’s IRB staff to attend IRB meetings at peer institutions so as to better assess best practices and to determine ways in which the University’s IRB can be improved.</td>
</tr>
<tr>
<td>3.2.8</td>
<td>IRB as an Investigative Body</td>
<td>34</td>
<td>Reconsider the reliance on IRB membership to staff ICs looking into incidents of noncompliance; a. Consider whether one or more non-IRB individuals might also be appointed to the ICs; b. If the University will continue to draw only from IRB membership to formulate these panels, expand the IRB membership to ensure sufficient expertise to meet this charge, a recommendation that was independently made in the foregoing section.</td>
</tr>
<tr>
<td>3.2.9</td>
<td>IRB as an Investigative Body</td>
<td>34</td>
<td>More rigorously make use of other internal resources (such as the PAR Monitoring Program discussed in section 3.3.3 below) and external resources to supplement the work of the ICs.</td>
</tr>
<tr>
<td>3.2.10</td>
<td>IRB as an Investigative Body</td>
<td>34</td>
<td>Evaluate the mechanisms through which IC findings and any corrective action required are disseminated, particularly with regard to follow-through with complainants.</td>
</tr>
<tr>
<td>3.3.1</td>
<td>Education and Training</td>
<td>39</td>
<td>Conduct an evaluation of the resources of the HRPP specifically dedicated to the education and training of the research community to ensure that appropriate resources are in place to offer basic and advanced training opportunities in human subjects’ protections.</td>
</tr>
<tr>
<td>3.3.2</td>
<td>Education and Training</td>
<td>39</td>
<td>Create opportunities for advanced training in human subjects protections for all individuals involved in human subjects protections including investigators, IRB members and staff, research personnel, and clinical staff on units that conduct research.</td>
</tr>
<tr>
<td>3.3.3</td>
<td>Education and Training</td>
<td>39</td>
<td>Evaluate whether additional mandatory training requirements, comparable to the new mandatory training for sponsor-investigators, should be implemented. Careful attention should be given to areas of research that are considered to be “high-risk,” including those involving vulnerable populations such as individuals with the potential for limited decision-making capacity.</td>
</tr>
<tr>
<td>3.3.4</td>
<td>Education and Training</td>
<td>39</td>
<td>Institute a more substantive requirement for advanced level training for investigators and research teams when a determination has been made by the IRB of serious or continuing noncompliance, and develop a mechanism for ensuring compliance with this requirement.</td>
</tr>
<tr>
<td>Section</td>
<td>Category</td>
<td>Credit Hours</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>------------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>3.3.5</td>
<td>Education and Training</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Evaluate the mechanisms through which HRPP policies and procedures are communicated to the broader University research community in order to ensure that all its members are knowledgeable about and have ready access to the policies and procedures related to human subjects research.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.6</td>
<td>Education and Training</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Create expectations for the involvement of research departments and centers in the development of educational programs tailored to the nature and context of their research activities.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.7</td>
<td>Education and Training</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consider ways to involve the University’s Center for Bioethics in the educational programs focusing on human subjects research.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.8</td>
<td>Education and Training</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consider efforts to engage the local community of patients and prospective subjects with programs on the ethics of research and the University’s HRPP.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.9</td>
<td>Education and Training</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upgrade and professionalize education in, among other subjects, the responsible conduct of research and research ethics.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.10</td>
<td>Scientific Review</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carefully consider the impact on the IRB’s overall ability to conduct an appropriate risk-benefit analysis when the evaluation of study merit is delegated to the department.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.11</td>
<td>Scientific Review</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carefully consider whether a robust review at the department level is feasible for each department, taking into considerable the size of the department, reporting relationships, and the volume of research.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.12</td>
<td>Scientific Review</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td></td>
<td>If the University chooses to maintain a department-based process for scientific review: a. Ensure the applicable policies delineate departmental and IRB responsibilities regarding the assessment of study design; b. Develop guidelines for careful scientific review and ensure that the de minimis requirements are adhered to when department-level scientific review is used.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.13</td>
<td>Scientific Review</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Revise the HRPP policy on scientific review and related guidance on the IRB’s website to state that individuals with a conflict of interest or conflict of commitment may not serve as a scientific reviewer. Conflict of interest should be operationally defined in these documents.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.14</td>
<td>Scientific Review</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Revise the template titled “Departmental Scientific Assessment Form” (used pursuant to Method 3) to ensure that this form includes a statement defining potential conflicts of interest and affirming that individuals with such a conflict of interest may not serve as a scientific reviewer.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.15</td>
<td>Scientific Review</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consider whether additional protections are needed to ensure that scientific reviews of research proposed by senior faculty are not reviewed by subordinates. Given these concerns, the University should determine whether department-based review is feasible for individual departments.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.16</td>
<td>Scientific Review</td>
<td>49</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Develop a mechanism for systematically incorporating scientific reviews into the IRB review process to ensure that scientific concerns impacting the criteria for IRB approval are sufficiently addressed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Type</td>
<td>Page</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------</td>
<td>------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>3.3.17</td>
<td>Scientific Review</td>
<td>49</td>
<td>Require that the IRB meeting minutes specifically document the IRB’s review of the scientific assessment documents and any substantive concerns raised in the course of this review.</td>
</tr>
<tr>
<td>3.3.18</td>
<td>Monitoring</td>
<td>54</td>
<td>Efforts to expand monitoring conducted through the PAR program and/or via the application of its methods to other HRPP monitoring efforts should be considered. Specific emphasis should be placed on increasing PAR monitoring efforts for research conducted at Fairview with an active dialogue with the Fairview staff so that they can be actively engaged in the process.</td>
</tr>
<tr>
<td>3.3.19</td>
<td>Monitoring</td>
<td>54</td>
<td>PAR should track and measure IRB follow-through on its findings and recommendations and report these to research leadership including department chairs and the Dean of the Medical School.</td>
</tr>
<tr>
<td>3.3.20</td>
<td>Monitoring</td>
<td>54</td>
<td>PAR should regularly share summary reports of its findings with department chairs and other institutional leaders charged with research oversight responsibilities to ensure that key areas of investigator and programmatic noncompliance can be readily identified and addressed.</td>
</tr>
<tr>
<td>3.3.21</td>
<td>Monitoring</td>
<td>54</td>
<td>Deficiencies in IRB review processes/functioning should also be addressed through existing reporting and supervisory hierarchies, and not be addressed solely within the more limited authority of the IRB and Office of the Vice President of Research.</td>
</tr>
<tr>
<td>3.3.22</td>
<td>Monitoring</td>
<td>54</td>
<td>In the context of ongoing concerns about problems related to subject recruitment and consent in psychiatric studies, PAR should include live consent monitoring of such studies in its repertoire of subject safeguards.</td>
</tr>
<tr>
<td>3.3.23</td>
<td>Monitoring</td>
<td>54</td>
<td>Separate reporting chains for IRB review and Post-Approval Review should be considered.</td>
</tr>
<tr>
<td>3.3.24</td>
<td>Engagement of Research participants</td>
<td>58</td>
<td>Establish accessible and reliable electronic and non-electronic channels (in addition to existing complaint mechanisms) for facilitating sustained communication among research participants, their family members and other advocates (within the permissible bounds of the Health Insurance Portability and Accountability Act (HIPAA)), researchers, research team members, and HRPP/IRB administration.</td>
</tr>
<tr>
<td>3.3.25</td>
<td>Engagement of Research participants</td>
<td>58</td>
<td>Develop mechanisms to regularly solicit, evaluate, and respond to research participant feedback.</td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
<td>Page</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>3.3.26</td>
<td>Engagement of Research participants</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Partner with researchers to incorporate mechanisms for soliciting feedback regarding the research participant experience so that it can be secured contemporaneously with the individual’s agreement to participate in research; for example, the HRPP might afford research participants an opportunity to complete a research participant satisfaction survey at the end of study participation, or add an option to the University’s template consent form asking subjects if they would agree to be contacted by the HRPP about their experiences as a research participant. Contact information for individuals who agree to this option could then be shared with HRPP officials and, post-participation, these individuals could be surveyed about their experiences. Data from these evaluations could be used to assess the research participant experience more broadly and would afford the HRPP a road map for developing programmatic changes that are directly responsive to the expressed needs of the research participant community.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.27</td>
<td>Engagement of Research participants</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Include members of the research participant community on relevant research related committees, task forces, and/or educational programs as another means by which researchers, research staff, research administrators, and University leadership can form relationships with them and thus more directly solicit their input on community priorities and areas of community concern.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3.28</td>
<td>Engagement of Research participants</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consider systematic approaches to express appreciation for subject participation, develop mechanisms to share research findings, and where appropriate, individual research results with subjects as a method of demonstrating partnership, showing respect and building trust.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.4.1</td>
<td>Capacity to consent</td>
<td>65</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Policies, guidance, application and review forms, and the IRB review process itself, should be redrafted and/or restructured for clarity and consistency to ensure that they will be appropriately used to prompt consideration of the methods used for assessing capacity to consent.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.4.2</td>
<td>Capacity to consent</td>
<td>65</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The IRB should ensure that its review includes a substantive assessment of the scope and appropriateness of protocol-specific procedures that address the capacity to consent in light of the subject population being approached.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.4.3</td>
<td>Capacity to consent</td>
<td>65</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Revised policies on legally effective informed consent should: a. provide the means for verifying decision-making capacity and voluntariness in all protocols as preconditions for all human subjects research; b. reject the standard that presumes capability by establishing a test of “substantial evidence otherwise” for adults with impairments.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.4.4</td>
<td>Capacity to consent</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The IRB must provide adequate review and oversight of its policies to ensure that they: a. align subject screening or other protections with the degree of risk involved in a study or the level of risk of impairment in a targeted or enrolled population; b. promote the use of strategies to support or enhance subject decision-making, including the advance selection of a surrogate decision-maker by a subject who may later lose decision making capacity.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.4.5</td>
<td>Vulnerability to Coercion</td>
<td>68</td>
<td>Develop standards that protect against real or perceived coercion in psychiatric treatment settings in which individuals may fear involuntary court proceedings.</td>
</tr>
<tr>
<td>3.4.6</td>
<td>Vulnerability to Coercion</td>
<td>68</td>
<td>Encourage and support the use of independent consent monitors, particularly in those cases where the treating physician is also the investigator, so as to minimize the possibility for undue influence or coercion.</td>
</tr>
<tr>
<td>3.4.7</td>
<td>Longitudinal Assessment of Capacity</td>
<td>69</td>
<td>IRB policies should more clearly require that protocols involving adults with potentially limited decision-making capacity include a plan for monitoring subjects who are likely to have fluctuating capacity, including the steps to be taken if capacity diminishes over the course of study participation.</td>
</tr>
<tr>
<td>3.4.8</td>
<td>Longitudinal Assessment of Capacity</td>
<td>69</td>
<td>IRB policies should more clearly require that protocols involving adults with potentially limited decision-making capacity specify the plan for re-consent when a subject regains capacity.</td>
</tr>
<tr>
<td>3.4.9</td>
<td>Legally Authorized Representatives</td>
<td>71</td>
<td>Policies and procedures related to the use of LARs must be comprehensively re-assessed in accordance with the foregoing observations and conclusions.</td>
</tr>
<tr>
<td>3.4.10</td>
<td>Legally Authorized Representatives</td>
<td>71</td>
<td>The OVPR and HRPP leadership should consider consultation with OHRP or DHHS on this topic.</td>
</tr>
<tr>
<td>3.4.11</td>
<td>Use of Surrogate Consent</td>
<td>73</td>
<td>The HRPP should develop effective strategies to educate research personnel on the legal use of surrogate decision-makers when considering the involvement of research participants with limited decision making capacity.</td>
</tr>
<tr>
<td>3.4.12</td>
<td>Use of Surrogate Consent</td>
<td>73</td>
<td>The IRB’s review of protocols proposing the use of surrogate decision-makers be rigorous and in keeping with applicable laws and best practices, as well as with University policies.</td>
</tr>
<tr>
<td>3.4.13</td>
<td>Use of Surrogate Consent</td>
<td>73</td>
<td>IRB policies should require: a. A process for informing prospective LARs about their responsibilities; b. Maximization of assent, with consideration of the use of an assent form in appropriate circumstances; c. A verification of the lack of dissent when assent is not possible; d. A plan for re-consent if a subject regains capacity; and e. A plan for monitoring subjects who are likely to have fluctuating capacity, including the steps to be taken if capacity diminishes.</td>
</tr>
<tr>
<td>3.5.1</td>
<td>Department of Psychiatry</td>
<td>84</td>
<td>IRB membership, expertise and training should more effectively address risk evaluation and management for psychiatric research.</td>
</tr>
<tr>
<td>3.5.2</td>
<td>Department of Psychiatry</td>
<td>84</td>
<td>Best practices regarding consent and capacity to consent should be introduced and made routine.</td>
</tr>
<tr>
<td>3.5.3</td>
<td>Department of Psychiatry</td>
<td>84</td>
<td>Fairview staff should be involved in protocol review, in gatekeeping functions, and in research monitoring.</td>
</tr>
<tr>
<td>3.5.4</td>
<td>Department of Psychiatry</td>
<td>84</td>
<td>[The investigators] as the focus of ongoing concern and criticism, should receive supervision, coaching in leadership, and advanced training in human subjects protections.</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------</td>
<td>----</td>
<td>---------------------------------------------------------------------</td>
</tr>
<tr>
<td>3.6.1</td>
<td>Institutional Culture</td>
<td>89</td>
<td>Define a hierarchy of accountability for human research ethics and thereby expand oversight responsibilities beyond the IRB. Department chairs should be expected to review and approve the submission of IRB protocols, be engaged in follow-up compliance activities, develop department-specific educational programs, and share ultimate responsibility for human subjects protections within their departments.</td>
</tr>
<tr>
<td>3.6.2</td>
<td>Institutional Culture</td>
<td>90</td>
<td>Rework institutional messaging in policies and procedure to include unequivocal statements on the administration’s intention to create and nurture a culture of ethics, and adopt communication strategies to bring these core values to life by investing in their visibility and adoption at all levels of the University community and beyond</td>
</tr>
<tr>
<td>3.6.3</td>
<td>Institutional Culture</td>
<td>90</td>
<td>Establish both formal and informal means of stimulating a university-wide conversation about the manner in which this newly endorsed culture of ethics can be most effectively realized.</td>
</tr>
</tbody>
</table>